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a mia Madre e mio Padre 
 
The ultimate measure of a man is not where he stands in moments of 
comfort and convenience but where he stands at times of challenge and 
controversy 
(la qualità di un uomo non si vede nei momenti di benessere e di comodità ma 
come si pone di fronte alle sfide ed alle controversie) 
 
The worth of an individual does not lie in the measure of his intellect, his 
racial origin, or his social position 
(il valore di un individuo non risiede nella misura del suo intelletto, nelle sue 
origini o nella sua posizione sociale) 
 
Martin Luther King Jr. 
 
 
a Davide e Gaia 
 
 
«Lungo il sentiero ripido e pietroso, ho incontrato una piccola bambina 
che portava sulla schiena il suo piccolo fratello. “Bambina mia - le ho 
detto - stai portando un pesante fardello!”. Lei mi ha guardato e ha 
detto: “Non è un fardello, signore, è mio fratello!”» 
 
Racconto di un missionario, Perù 
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SUMMARY 
 
Surveying literature data, what emerges is that cellular function and phenotype are highly 
influenced by cell surface proteoglycans (PGs), present at the cell-tissue-organ interface 
where they are thought to have crucial regulatory roles in cellular control and in 
coordinating and directing appropriate response to multiple ligands in normal 
physiological processes and pathological conditions, including the processes of tumor 
onset and progression. The complexity of PG surface pattern in tumour cells, especially 
that provided by glypicans, syndecans and NG2, enables them to modulate directly or 
indirectly several aspects of the tumour cell phenotype, including growth kinetics, 
invasiveness and metastatic potential. Recent evidence further highlights the fact that 
cancer cells, as part of the transformation process, alter their cell surface PG profile, but 
also alters the fine structure of a given proteoglycans and the tumorigenic function of the 
11 primary PGs, including syndecans-1-4, glypicans-1-6 and NG2, is only in part 
resolved for some of these PGs individually, but is obscure when considering these 
molecules cumulatively. In this context, we have focused our research on trying to 
understand how a given cell surface PG pattern may be involved in tumour growth and 
metastasis in sarcomas and whether they could represent new potential 
prognostic/predictive markers in defined class of patients with oral squamous cell 
carcinomas (OSCC). We have approached this problem defining systematically the 
constitutive pattern of cell surface PG expression in a large panel of sarcoma cells and 
OSCC biopsies combining analyses at the transcript and immunochemical level and by 
creating 143B osteosarcoma cells over-expressing glypican-5. This engineered cellular 
model was then assayed for its adhesion and migratory abilities in response to isolated 
molecules of the extracellular matrix in vitro. Misexpression of glypican-5 on defined 
constitutive PG backgrounds modulates the in vitro behavior of the cells. The outcome of 
this project could provide the preliminary evidence that defined surface PGs pattern could 
differentially control cancer cells behavior and could be a new perspective in the 
understanding how these molecules regulate different aspects of cancer biology. 
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1.1   PROTEOGLYCANS  
 
Proteoglycans (PGs) represent a special class of glycoproteins that are heavily 
glycosylated. They consist of a core protein with one or more covalently attached 
glycosaminoglycan (GAG) chain(s). These glycosaminoglycan chains are long, linear 
carbohydrate polymers that are negatively charged under physiological conditions, due to 
the occurrence of sulfate and uronic acid groups. The biosynthesis of PGs, in addition to 
the ordinary biosynthetic processes of O- and N-linked oligosaccharide components as in 
other glycoproteins, further requires biosynthesis of GAG in the Golgi apparatus, which 
can be considered to be a most complex biosynthetic process for complex carbohydrates. 
It requires a number of glycosyltransferases and sulfotransferases and involves multiple 
sub regions of the Golgi apparatus, which poses a great challenge for researchers in 
elucidating the organization and regulatory mechanisms involved in PG biosynthesis. 
PGs have been originally classified according to the nature of their glycosaminoglycan 
chains (Figure 1): chondroitin sulfate, dermatan sulfate, heparin/heparan sulfate, keratan 
sulfate. Proteoglycans have also been subdivided according to their position in relation to 
the cell and by size. Extracellular PGs include large PGs of the hyalectan family (e.g. 
aggrecan, versican), basement membrane PGs (perlecan, agrin, bamacan) and small 
leucine-rich proteoglycans (SLRP). Several collagen types (IX, XII, XIV, and XVIII) 
have been shown to carry GAG chains and may therefore be considered “pseudo-PGs”. 
Several extracellular PGs do not belong to any family, they are often presented as ‘part-
time’ or ‘facultative’ PGs (CSF-1, M-CSF, claustrin). The non-classified PGs include 
thrombomodulin and several neural PGs: neuroglycan, phosphacan, brevican1,2. 
Hematopoietic cells also contain a secretory vesicle proteoglycan known as serglycin1. 
Several excellent reviews describe the properties and structural-functional peculiarities of 
PGs3,4,5,6,7,8. The heterogeneity of GAGs and the existence of more than 50 genes coding 
for PGs give a plethora of molecular properties for these macromolecules. Often, the 
property of an isolated GAG chain is contradictory to those of the same chain attached to 
the protein core of PGs9. Individual functions of proteoglycans can be attributed to either 
the protein core or the attached GAG chain10,11. They hold a large number of water 
molecules in their molecular domain and occupy enormous hydrodynamic space in 
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solution. Another remarkable property of the glycosaminoglycans, which is particularly 
significant in heparan sulfate and heparin, is their capability to specifically interact with a 
number of important growth factors and functional proteins.  
 
 
From: Kleene, R., Schachner, M. Nature Reviews Neuroscience 5, 195-208 (March 2004) 
 
Figure 1: Schematic structure of glycosaminoglycan and proteoglycan. Hyaluronian is not a PG linked to 
GAG and is free-standing thin filaments assembled in the ECM and around the cells.  
 
 
Proteoglycans are a major component of the animal extracellular matrix, the "filler" 
substance existing between cells in an organism. Here they form large complexes, with 
other proteoglycans by binding filaments and by linking to matrix proteins (such as 
Collagen). There is evidence that they can affect the activity and stability of proteins and 
signalling molecules within the matrix. They are also involved in binding cations (such as 
sodium, potassium and calcium) and water, and may regulate displacement of molecules 
through the matrix (Table 1). The HS chains at the cell surface are mostly attached to 
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syndecan and glypican core proteins. These core proteins determine the proximity of the 
HS chains to the cell surface, when, where, and to what extent the HS chains are 
expressed and the rate and mechanism of HS turnover12. Heparan sulphate-bearing 
proteoglycans (HSPGs) are divided into three subfamilies: the membrane-spanning 
proteoglycans (syndecans, betaglycan and cell membrane hyalectans as CD44), the 
glycophosphatidyl-inositol (GPI)-linked proteoglycans (glypicans) and the secreted 
extracellular matrix (ECM) proteoglycans. The HS chains are assembled on core protein 
by enzymes in the Golgi, using nucleotide sugar imported from the cytoplasm. There is 
great structure heterogeneity in term of chain length and size (examples of large 
proteoglycans are aggrecan, the major proteoglycan in cartilage, and versican, present in 
many adult tissues including blood vessels and skin. The small leucine rich repeat 
proteoglycans (SLRPs) include decorin, biglycan, fibromodulin and lumican), the 
modification on the chains (deacetylation, sulphation and epimerization) and spacing of 
the modified tracts1. Because of their negative charge, the HS chains bind a very wide 
type of proteins, including the members of the fibroblast growth factor (FGF) family and 
their receptor tyrosine kinase, transforming growth factors (TGFs), bone morphogenetic 
proteins (BMPs), Wnt proteins, chemokines and interleukins, as well as enzyme 
inhibitors, lipases an apolipoproteins and ECM an plasma proteins. Many functions of 
HSPGs depend on interaction of the core protein. For example, HSPGs at the plasma 
membrane can transfer spatial information about a cell’s environment and either activate 
adhesion mechanisms or enhance cell motility. Often, signaling through HSPGs in this 
context occurs in collaboration with other cell-surface receptor (e.g. integrins) to 
facilitate cell attachment, spreading and motility1 (Table 2). 
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Table 1: Some of the putative molecular interactions of exhibited by the side chains of PGs 
 
GAG ECM components Signalling molecules Cell adhesion 
molécules 
Other molecules 
Heparin 
heparan 
sulphate 
Fibronectin 
Fibrin 
Collagen types I, III, V 
Laminin-1 
Pleiotropin 
Tenascins-C, -R 
Thrombospondin 
Vitronectin 
Fibrillin-1 
Fibulin-2 
Slit-1,-2 
FGF family members 
1-24 (?) 
HB-EGF 
HGF/SF 
IGF-I, IGF-II 
Wnt1, Wnt3a 
 (other Wnts ?) 
Chordin 
Noggin 
Slit/Robo 
Interferon γ 
PDGF 
SDGF 
VEGF 
TGF β 1,2 
Midkine 
Pleiotropin 
Angiopoietin-3 
GM-CSF 
IL-8 
IP-10 
MCP-1, -4 
RANTES 
TNFα β 
N-CAM 
L-selectin 
P-selectin 
MAC-1 
PECAM-1 
Acetyl cholinesterase 
Thrombin 
Lipoprotein Lipases 
Heparin Cofactor II 
Neutrophil elastase 
Plasminogen-Activator 
Inhibitor 
MMP7 
TPA 
ApoB 
ApoE 
Amyloid-precursor protein 
Amyloid-precursor-like 
protein-2 
Cathepsin-X 
Viral coat proteins (Tat, 
papilloma virus, 
cytomegalovirus) 
Microbes and microbial 
products 
 
Chondroitin 
sulphate HA Tenascins-C, -R 
CMP 
Fibulin-1, -2 
Fibronectin 
Fibrillin-1 
Amphoterin 
Collagen types V, VI 
 
HB-GAM/PTN 
FGF-2, -16, -18 
PDGF-AA 
Angiostatin 
Midkine 
Pleiotropin 
Amphoterin 
HB-EGF 
VEGF 
SLC 
IP-10  
SDF-1ß 
N-CAM 
Integrins  
(α5β1/α4β1) 
CD44 
PDGFRα 
FGF receptor-1, -3 
MT3-MMP 
GRIP-1 
LDL 
Glycolipids 
Dermatan 
sulphate 
Collagen types I, II, 
VI, XII 
Matrilin 1 
Tropoelastin 
Matrix Glycoprotein-1 
Fibronectin 
Tenascin-X 
FGF-1, -2, -7 
HGF/SF 
TGFβ 
PF-4 
SLC 
IP-10  
SDF-1ß 
RANTES 
ICAM-1 
L-selectin 
P-selectin, 
CD44 
Heparin Cofactor II 
Thrombin 
Activated Protein C 
Protein C inhibitor 
LDL and HDL 
 
Keratin 
sulphate(s) 
Collagens    
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Table 2: Predicted functional traits of primary HSPGs involved in the regulation of cell movement1 
 
HSPGs 
Non 
permissive 
directional 
cue2 
ECM 
linker of 
direction-
promoting 
cues3 
Cryptic 
motility-
promoting 
factor4 
Shedded 
motility-
inhibitor5 
Cell 
surface 
interactor6 
Enhancer of 
signal 
transduction7 
Cell-
ECM 
co-
receptor8 
CD44    (X) X X X 
perlecan X X X     
syndecan-1    X X X X 
syndecan-2    X X X X 
syndecan-3    (X)  (X) X 
syndecan-4    (X) X X X 
glypican-1     X   
glypican-2 X X   X  X 
glypican-3    X X   
 
 
1Based upon both published and unpublished observations; 2Regulator of directionality of cell migration by acting as a 
non-permissive ECM substrate component; 3Capable of sequestering chemotactic molecules and cell growth- and 
motility-promoting factors in the ECM; 4Promoter of cell motility following proteolysis; 5Acting as motility-inhibiting 
factor when shedded from the cell surface; 6Engaded in multivalent interactions with cell surface components directly 
or indirectly involved in the control of cell motility; 7Directly mediating signal transduction cascades involved in the 
regulation of cell movement; 8Specifically serving as co-receptor for ECM components and thereby implicated in the 
regulation of cell movement. 
 
 In addition to their structural domains, HS core proteins are all posttranslationally 
regulated; particularly all HS core proteins can be shed from the cell surface. In many 
cases, shedding converts the HSPG from an activator to a potent inhibitor13,14. Shedding 
of syndecan itself is tightly regulated15 and can be used by pathogens as a means of 
cellular entry16. Syndecans shedding is stimulated by epithelial wounding, where release 
from the cell surface is mediated by matrix metalloproteinases. In mammalian 
physiology, protein-HSPGs interactions promote activities specific to each organ system 
to regulate metabolism, transport, information transfer, support and regulation at the 
systemic level as well as cellular level1,17,18. HSPGs are also gradually emerging as key 
regulators of tumour progression and several of them are assuming important roles as 
prognostic factors.  
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1.2  SYNDECAN FAMILY 
 
Syndecans represent a four-member subfamily of highly conserved type I transmembrane 
heparan sulfate PGs and are expressed on virtually all cell types throughout development 
and adulthood. The syndecans’ core proteins show a high degree of conservation in the 
cytoplasmic domain (ca. 30 amino acids) and transmembrane domain and this suggests 
that 4 genes arose from an ancestral common gene and sequent divergent evolution and 
duplication: syndecan-1 with syndecan-3 and syndecan-2 with syndecan-4. The 
cytoplasmic domain is partitioned in three regions: C1 (juxtamembrane region) and C2 
(C-terminal region) conserved, V (intervening region) variable and different for each 
syndecan, but conserved across species. C2 region has the amino acid sequence EFYA 
which binds PDZ (PSD-95, Dlg, ZO-1) domains present in specific proteins, like 
Ca++/Calmodulin-dependent serin protein Kinase (CASK)19 (Figure 2). This binding 
allows assembling protein complexes on the inner surface of the plasma membrane and to 
link membrane components to the actin microfilament of the cytoskeleton. 
Figure 2: A schematic view of a syndecan, showing the core protein and glycosaminoglycan chains. 
Potential interactions, where known, are indicated. CS, chondroitin sulphate; ECTO, ectodomain; HS, 
heparan sulphate; TM, transmembrane domain; C1 and C2 refer to conserved regions 1 and 2, and V refers 
to the variable region, of the cytoplasmic domain 
 
From: Couchman, J.R. Nature Reviews Molecular Cell Biology, 4: 926-938 (Dec 2003) 
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Each member of the family has a distinct temporal-spatial pattern of expression. 
Syndecan-1 is expressed predominantly in epithelial at the basolateral surface of cells and 
mesenchymal tissue and in in vitro malignant transformation syndecan expression is 
associated with maintenance of epithelial morphology, anchorage-dependent growth and 
inhibition of invasiveness; down-regulation in syndecan-1 expression shows a cell 
transformation from epithelial to mesenchymal and increased invasion 20,21. In contrast to 
the general notion that the syndecan may be inhibitor of tumorigenensis, syndecan-1 
shows a dual role because its enhanced expression has also been observed in gastric22 and 
breast23 carcinomas and this over-expression correlates with tumor aggressiveness and 
poor clinical prognosis. Syndecan-2, originally described as fibroglycan on fibroblast 
where it has been implicated in matrix assembly24,25, also has important functions in 
nervous system; is expressed predominantly in embryonic development and recently it is 
suggest its role in regulation of TGF-β signaling26; syndecan-2 has a second role in 
adhesion and proliferation of colon carcinoma cells where is over-expressed27. Syndecan-
3 plays an important role in regulation of skeletal muscle differentiation and 
development; also appears to be involved in regulation of Hh signaling and in 
mammalian one member of this family, indian Hh (iHh) is spatial-temporal regulated by 
syndecan-326. Syndecan-3 is also found in the nervous system, where binds heparin-
binding growth associated molecule (HB-GAM) in outgrowing axonal tracts of the 
developing thalamocortical pathway of the rat25,28. Syndecan-4 is the most studied 
member of the syndecan family and has a various activities, including modulation of 
FGF2 signaling, regulation of cell migration via β2 integrin, control of adhesion via 
cytoskeletal modifications and its plasma membrane localization and participation in 
FGF2 endocytosis underlines its eventual relationship to lipid rafts, plasma membrane 
domain that provide internalization of membrane components29; another role of 
syndecan-4 involves regulation of fibronectin signaling and matrix contraction together 
with tenascin-C30. Up-regulation of syndecan-4 has been noted in hepatocellular 
carcinomas and malignant mesotheliomas31 and such over-expression may correlate with 
increased tumor cell proliferation32. Furthermore, syndecans are shedded from cell 
surface via cleavage of their ectodomain; this process allows that free ectodomain play as 
a soluble regulatory macromolecules role33. Summarizing, the core proteins of syndecans 
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are involved in many signaling function that translate information to the cytosol from 
extracellular environment trough their heparan sulfate chains; nevertheless these 
informations, the mechanism which cooperate with integrin become unknown (Figure 3).  
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Figure 3: Schematic overview of the putative molecular functions of syndecans; they may participate in 
growth factors/cytokine signalling events through their HS chains and may additionally link to the same 
ECM components. Either individually or through a putative cooperation, syndecans strongly impact on 
cytoskeletal dynamics through phosphorylation events taken place in the cytoplasmic tail. 
 
 
 
 
 
 
1.3  GLYPICAN FAMILY 
 
The name glypican identifies a family of HSPGs that are linked to the cell surface of the 
plasma membrane through a covalent glycosyl-phosphatidylinositol (GPI) linkage34,35. 
Six glypicans have been identified in mammals so far (GPC1 to GPC6)36,37,38,39,40. The 
size of core protein of glypicans is similar (60 to 70 KDa) and they all contain an N-
terminal secretory signal peptide and a hydrophobic domain in the C-terminal region 
required for the insertion of the GPI anchor. 
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From: Song and Filmus, Biochimica et Biophysica Acta, 1573 (2002), 241-246 
 
Figure 4: General schematic structure of glypican core proteins. 
 
Although the degree of amino acid homology between most glypican is moderate, the 
localization of 14 cysteine residues which are believed to form intramolecular disulfide 
bonds, giving all glypicans a conserved three-dimensional structure41,42,43. In addition to 
the GAG-link region, the mature core proteins have other two structural domains: the 
linker domain and an N-terminal globular domain identificated for an internal cleavage 
site in GPC1, GPC3, GPC4 and GPC536,44,45,46,47; this reported cleavage site map in the 
same region between globular domain and linker domain and the significance of this 
proteolysis and the enzyme responsible is unknown. It’s to point out that the 30-40 KDa 
cleavage product that is generated from the N-terminal of the protein remains attached to 
its C-terminal half through some disulfide bridges, as it is generally undetectable during 
Western blotting without reducing condition36. Another characteristic shared by all 
glypicans is the localization of the insertion sites for the HS chains, which seems to be 
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restricted to the last 50 amino acids in the C-terminus, place the chains close to the cell 
membranes34,42. Although there are vary degrees of glycosylation, all mature glypican 
protein cores are plus/minus 500 amino acids. The degree of amino acids homology 
between the glypican family tend to show the separation in two major group. The first 
group including glypican-1, gypican-2, glypican-4 and glypican-6 with 35%-63% 
sequence similarity; the second is comprised of glypican-3 and glypian-5, which are 54% 
similar37, whereas the homology between of the two groups is only 17%-25%. In addition 
to the similarities in protein sequences, one of the typical element is the GPI anchor, 
which significance has not been clearly defined (Figure 5). 
 
 
Figure 5: Structure of GPI anchor (From: www.hmds.org.uk) 
 
There are some hypothesis about that: first is that the lipid-anchor targeting the glypican 
in specific areas of the cell membrane called “raft”48,49 involved in Ca++ influx, the 
second possible role is their function in the release of the proteins in the extracellular 
environment by shedding, and the third hypothesis concern their recycling to the cell 
surface via endocytosis50 regulating in this way receptor-mediated endocytosis and the 
uptake of molecules from extracellular environment. Particularly, the lipid anchor can be 
removed by proteases or lipases leading to shedding of glypican from the plasma 
membrane to generate either soluble or glypicans form associated with low-density 
particles. Recent studies unveil the cell-autonomous functions of glypican released that 
can be transported across tissue and elicit their function in a broader field of cells51,52. 
Recently, it was been demonstrate that a protein called Notum, an alpha/beta-hydrolase 
cleaves GPI anchor protein in mammalian and this process is direct correlate with 
inositol 
glycan 
ethanolamine 
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signaling of Wnt53, where in Drosophila Notum was identificated as a novel inhibitor of 
Wnt signalling by modifying the HS chains of Drosophila glypicans54,55, but remains 
unclear whether Notum is able to cleave glypicans from mammalian cells56. In general, 
glypicans are expressed predominantly during development41. In most cases where 
detailed studies have been performed, expression levels have been shown to change in a 
stage- and tissue-specific manner, suggesting that glypicans are involved in 
morphogenesis38,43,57,58. Glypicans appears to be expressed in spatial-temporal manner 
within developing tissue also through the passage from embryonic to adult (Table 3). 
 
Table 3: Differential expression of glypicans during mammalian development 
 
Name Original designation 
Expression in 
embryo Expression in adult Reference 
glypican-1 Glypican 
Bone, bone marrow, 
muscle epidermis, 
kidney 
Most tissues David et al., 1990; Litwack et al., 1994 
glypican-2 Cerebroglycan Nervous system Not detected Stipp et al., 1994; Ivins et al., 1997 
glypican-3 OCI-5 Most tissues 
Ovary, mammary gland, 
mesothelium, lung, 
kidney 
Filmus et al., 1998; Pellegrini et al., 1998; 
Li et al., 1997; Filmus (unpublished 
observations) 
glypican-4 K-glypican Brain, kidney, lung Most tissues Watanabe et al., 1995; Veugelers et al., 1998; Siebertz et al., 1999 
glypican-5  Brain, lung, liver, kidney, limb Brain 
Veugelers et al., 1997; Saunders et al., 
1997 
glypican-6 
 
 
Many tissues, 
including liver and 
kidney 
Many tissues including 
ovary, kidney, liver, and 
intestine 
 
Paine-Saunders et al., 1999; Veugelers et 
al., 1999 
 
 
From: Jorge Filmus. Glycobiology 2001 11: 19R-23R 
 
 
The role that they have in development embryonic and at last in tumour development is 
still unknown for the most of the glypicans, with the exception of glypican-3, for which 
there is a particular interest because is direct involved in Simpson-Golabi-Bhemel 
Syndrome59 and for its high expression during mammalian development in most tissue 
except for the nervous system60 (whereas in adult GPC3 expression is detected in very 
limited number of tissue) (Table 4).  
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Table 4: Clinical applications of glypicans in oncology 
 
PG Diagnostic Predictive/prognostic 
glypican-1 ? Pancreatic carcinoma 
glypican-2 ?  
glypican-3 Hepatocarcinoma (Melanoma) Hepatocarcinoma 
glypican-4 ? ? 
glypican-5 ? ? 
glypican-6 ? ? 
 
While studies on ovarian cancer cell lines, mesotheliomas, and breast tumors have 
demonstrated the down-regulation of GPC361,62,63, other investigations on hepatocellular 
carcinoma have shown a marked elevation of GPC3 mRNA over the level observed in 
corresponding normal tissues64,65,66,67 and GPC3 exhibits a diffuse and uniform 
distribution within individual tumors. The expression appeared to bear no relation to the 
size of the hepatocellular carcinoma and was observed even in small-sized tumors68. 
Besides, up-regulation of GPC3 in hepatocellular carcinoma can also be observed at the 
protein level69. Capurro et Al.70 observed that by staining fixed tissue sections, 72% 
hepatocellular carcinoma sections display GPC3 expression, whereas this protein was 
undetectable in hepatocytes from normal liver and benign liver diseases. Moreover, by 
using an ELISA, they found that whereas GPC3 is undetectable in the serum of healthy 
donors and patients with hepatitis, its levels were significantly increased in 53% with 
hepatocellular carcinoma. Similar results have also been reported independently by two 
other groups71,72. Based on these results, it has been proposed that GPC3 could be used as 
a serum and histochemical marker for hepatocellular carcinoma69,71 and it was 
demonstrate that GPC3 forms a complex with Wnts. Glypican-1 displays high levels of 
expression throughout the brain and skeletal system73, in which the major expression is 
observed in osteoblast, developing skeletal and smooth muscle. To note that GPC1 
expression is very little in embryonic cardiomyocytes, but strong detected in neonatal and 
adult heart of Drosophila74. GPC1 has an important role in the pancreatic cancer cell 
invasion and metastasis, because it was showed that glypican-1 and syndecan-1 are 
shedded by these cancer cells75,76,77 and GPC1 down-regulation suppresses pancreatic 
cancer cell growth and slightly modifies signaling of members of the TGF-beta family of 
growth factors78. GPC2 expression is restricted to the developing neuronal tissue, like 
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brain, spinal cord, dorsal root ganglia and cranial nerves and is not present in the 
corresponding adult tissue; its down-regulation seems to follow the migration and 
maturation of neurons79. GPC4 show a limited pattern of embryonic expression36; in 
developing brain glypican-4 is highly produced by neural precursor cell and its 
expression fall off during differentiation80; is present at high levels in the developing 
kidney and regulates hepatocyte growth factor-mediated morphogenesis in renal 
epithelial cells81. Briefly, GPC5 is found in restricted number of organs in embryo38 and 
during early development glypican-5 is expressed with the onset of mesenchymal 
proliferation and condensation. GPC5 expression is very limited in developing central 
nervous system, but in adult its expression is more widespread. GPC6, like GPC5, is 
found in condensing mesenchyme surrounding bronchi (i.e.)37 and strong expression is 
observed also in other district, like developing gastrointestinal tract or in subendothelial 
smooth muscle cell layers of major blood vessels37. Although, in general, the expression 
of glypicans seems to be involved in cell proliferation and migration, the ways with 
which they acts are more complex, for example GPC1 and GPC4 are involved in 
proliferation of neural precursor cell, while GPC2 seems to inhibit this process61,63,64. 
Moreover some proteins of this family can play a double role, because they can acts both 
stimulating proliferation and like tumour suppressor of the ectopic signals produced by 
either their loss- or gain-of function82 in relation to tissue or cellular context62 (Figure 6). 
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Figure 6: Schematic overview of the putative molecular functions of the GPI-linked PGs; similarly to 
syndecans through their HS chains they are believed to sequester a variety of growth factors and they are 
postulated to be involved in cell-ECM interactions 
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 1.3.1  GLYPICAN-5 
 
Glypican-5 was identified and characterized the first time using the strategy of screening 
the partial cDNA sequences available in the expressed sequence-tagged database 
(dbEST)83 and was showed that this new member of glypican family had all the structural 
features characteristic of the other glypicans (Figure 7). 
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Figure 7: Schematic overview of the putative molecular functions of glypican-5. 
 
 
Glypican-5 is localized on chromosome 13q32, the same chromosomal band containing 
glypican-6 gene, and is most closely related to glypican-3: GPC3 and GPC5 are similar in 
C-terminal glycanation domain where the Ser-Gly repeat sequences appear split by a 
cluster of acidic residues that are flanked by cysteines (to form an acidic bulge on the 
protein); this is in contrast of GPC1 and GPC4 that have this Ser-Gly repeat sequences in 
front of this bulge46. Clustering of the GPC5/GPC6 genes on chromosome 13q32 is 
strongly reminiscent of the clustering of the GPC3/GPC4 genes on chromosome Xq26 
and suggests GPCs arose from a series of gene and genome duplications. Based on 
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similarities in sequence and gene organization, glypican-1, glypican-2, glypican-4, and 
glypican-6 appear to define a subfamily of glypicans, differing from the subfamily 
comprising so far glypican-3 and glypican-537 (Figure 8). 
 
Figure 8: Glypican family phylogenetic tree. Multiple Sequence Alignment by CLUSTALW 
 
Glypican-5 is expressed, like other glypicans, in highly tissue-specific manner during 
embryogenesis. In the earliest stage of mouse embryo limb, GPC5 mRNA is localized to 
highly proliferative cells that are in the process of generating differentiated structures and 
GPC5 expression becomes restricted when undifferentiated, proliferative mesenchyme of 
the developing limb bud starts to become differentiated skeletal and connective tissue 
elements. Like this, glypican-5 mRNA expression is localized in highly proliferative cells 
in kidney; although this observation link GPC5 expression with proliferative cells in limb 
and kidney embryo, glypican-5 function is unrelated with proliferation because in the cell 
layers of the central nervous system of embryo where are confined the most neural 
proliferation, GPC5 expression is missed38. In general, GPC5 expression marks, in the 
early nervous system, distinct subset of newly generated postmitotic neurons; only in 
later embryonic and perinatal life does glypican-5 begin to be widely expressed 
throughout the brain38. These shift in the expression of glypican-5 during embryogenesis 
are different, and in some sense complementary to, those showed from other glypicans: 
glypican-2 is expressed in developing neurons until they become postmitotic an then its 
expression rapidly disappears39,63. Glypican-1 mRNA expression seems appears later than 
GPC2 expression, but its expression level increase in adult brain84. Saunders et al.38 
hypothesize a tidy model of temporal expression: in developing neurons, first appears 
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GPC2 expression, then GPC5 and at least are predominantly GPC1 expression; the 
significance of this pattern remain still unclear. Deletions instead in the long arm of 
chromosome 13 (where map glypican-5 and glypican-6 gene) was associated with 
developmental abnormalities known as 13q- syndrome85,86 and glypican-5 seems to act, 
like glypican-3, as indirect regulator of cell proliferation and a direct regulator of 
differentiation. Glypican-5 is also implicated as possible target for the 13q31-q32 
amplification detected in lymphoma cell lines87 where, through CGH (comparative 
genomic hybridization) analysis have detected gains of copy number on this 
chromosomal region and GPC5 is over-expressed and it may contributes to development 
and/or progression playing an important role in pathogenesis of  lymphomas, in mantle 
cell lymphoma (MCL, an aggressive non-Hodgkin’s lymphoma) and multiple B-cell 
lymphomas88,89 and other tumors71. Recently, it was reported that genomic amplification 
of 13q31-q32 is associated also with rhabdomyosarcomas; genomic copy number and 
gene expression analyses of rhabdomyosarcomas indicate that GPC5 is the only gene 
consistently expressed and up-regulated in all cases with amplification90. 
 
 
1.4  CELL SURFACE HSPGs SIGNALLING AND INTERACTION WITH . . . . 
. .     THE ECM 
 
HSPGs are present on the surface of every eukaryotic cell, including both tumour cells 
and cells that are important for tumour survival. Heparan-sulphate proteoglycans on the 
tumour cells surface have been shown to be important in many aspects of tumour 
phenotype and development, including cellular transformation, tumour growth, invasion 
and metastasis. Specifically, certain HSPGs sequences that are expressed on the tumour 
cell surface seems to be pro-tumorigenic; by dynamically regulating the composition and 
sequence of HSPGs, cancer cell modulate their growth kinetics and metastatic potential. 
HSPGs on the surface of tumour cell seems to mediate their effects by regulating growth 
factor signalling, cell adhesion, proliferation and migration and angiogenesis91,92 (Figure 
9). 
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From:  Bishop, J.R., Schuksz, M. & Esko, J.D. Nature 446, 1030-1037(26 April 2007) 
 
Figure 9: HSPGs function as co-receptors for growth factors and their receptor tyrosine kinases, which are 
present either on the same cell a) or on adjacent cells b). They transport chemokines across cells c) and 
present them at the cell surface d). A proteolytic processing lead to the shedding of syndecans and 
glypicans from the cell surface e), and heparanase cleaves the HS chains f), liberating bound ligands (such 
as growth factors). Cell-surface HSPGs are actively taken up by endocytosis g) and can recycle back to the 
surface or be degraded in lysosomes h). HSPGs also facilitate cell adhesion to the extracellular matrix i) 
and form bridges to the cytoskeleton j). Secreted HSPGs are involved in the formation of organized 
extracellular matrices that form physiological barriers k) and sequester growth factors and morphogens for 
later release l). Serglycin carrying highly sulphated heparin chains is packaged into secretory granules of 
hematopoietic cells m). Finally, some experiments suggest that HS chains exist in the nucleus n), although 
their function in this location is unknown. 
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As a consequence, alteration in the level of expression of the core protein, as well as 
GAG structure and/or density on HSPGs, can potentially make cancer cell highly 
versatile in modulating their behaviour75.  Based on the information about the immense 
structural diversity of HSPGs, these molecules are able to bind and interact with a wide 
variety of proteins, such as growth factors, chemokines, morphogens and enzymes. 
Growth factors, such as fibroblast growth factors (FGF1 and FGF2), vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF), transforming growth factor-β 
(TGFβ) and platelet-derived growth factor (PDGF)93 have an important role in signalling 
mediated by HSPGs, particularly growth factor signaling seems to be delicately 
controlled by an auto-regulatory loop involving the syndecan and glypican expression 
levels on the cell surface and their role in endocytosis of receptor-ligand 
complexes94,95,96. Several classes of growth factors, including heparin-binding members 
of the EGF family, such as heparin-binding EGF-like growth factor (HB-EGF), HGF, 
Wnts, Hedgehogs and some members of the TGFβ superfamily seem to dependent upon 
the interaction with heparan sulfate chains of surface PGs for optimal triggering of signal 
transduction inside the cell52,97,98,99. These specific interactions allow HSPGs to “fine-
tune” protein function and regulate diverse biological processes75. The unique structural 
complexity of tumour-cell HSPGs, enable them to modulate directly and/or indirectly 
several aspects of tumour-cell phenotype, including growth kinetics, invasiveness and 
metastatic potential75,76. In this way, a specific pattern of a cell surface HSPGs can be 
pro-tumorigenic or anti-tumorigenic depending on whether present in the ECM can binds 
the GAGs chain of HSPGs or on whether in the ECM can binds the cell surface receptors, 
which link membrane HSPGs as co-receptor. Recently, it was highlight that cancer cell, 
as a part of transformation process, alter their cell surface heparan-sulphate proteoglycans 
profile including differential expression of particular proteoglycan core protein 
sequences100; glypicans have also been found to modify cellular response to bone 
morphogenetic protein (BMP)101 and insulin-like growth factors-2 (IGF-2) that are 
important in cellular division and differentiation75. Other important role involved HSPGs 
in regulating morphogen gradients, where unknown heparan-sulphate proteoglycan affect 
Indian hedgehog (IHH), a protein that control proliferation, hypertrophy and ossification 
of chondrocytes1. Particularly, syndecans can ”cross-talk” with other cells or with 
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element of extracellular environment and transduct directly the information into the cell 
through their intracellular domain. Otherwise, glypicans cant’ operate directly in signal 
transduction, because they lack the intracellular domain; both syndecans and glypicans 
can mediate the passage of the information from out to in of the cell acting vicariously as 
co-receptor with cell membrane receptor for signal molecules. Other ways which 
syndecans and glypicans can relay our contribute to signal transduction are their shedding 
in the extracellular environment or their internalization within the endocytotic vesicle, in 
which the GPI-anchored protein can be endocytosed and degraded, cleaved and released, 
vesiculated, or exchanged onto another cell102 
 
 
1.5  SIGNALING  MEDIATED BY GLYPICANS 
 
The GPI anchor is one of crucial elements that could make glypicans susceptible to 
additional post-translational modifications. Particularly, the GPI anchor appears to 
provide a system of regulated release of glypicans to the extracellular environment: the 
lipid anchor can be removed by protease or lipase leading the shedding of them from the 
plasma membrane to generate either soluble or glypican form associated with low-density 
particles66. Proteolytic cleavage of the core protein can also contribute to generate distinct 
glypicans form. Once secreted, regulatory signal peptides bind to cell membrane 
receptors and activate specific intracellular cascades, thus determining cell fate103; the 
extracellular signals can act both at short and long distances by either acting on cells near 
the producing source or on those more distant to it. As consequence of it, short- and long-
range signaling trigger distinct biological outcome according to the spatial position of 
targeted cells87. There are different enzyme that can cleave glypicans GPI anchor from 
cell surface, and two of them are endogenous GPI-PLD (phospholipase D) and one of 
recent discovery called Notum (an alpha/beta-hydrolase)54,55,104 (Figure 10) is to 
underlined that mammalian Notum is active in the extracellular environment and has a 
cleavage site in the GPI anchor similar to that of GPI-PLC (phospholipase C)56; on the 
contrary of Notum, GPI-PLD seems to be active only in the intracellular 
environment53,56,88,105. 
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From: Häcker, U., Nybakken, K., & Perrimon, N. Nat. Rev. Mol. Cell Biol. 6, 530-541 (July 2005) 
 
Figure 10: a) Glypicans function as low-affinity binding proteins for secreted morphogens. Glypicans 
maintain secreted signalling molecules at the cell surface at levels that are sufficient to activate high-
affinity signalling receptors and ensure activation of target genes. b) In the absence of glypican core protein 
or sufficiently sulphated glycosaminoglycan (GAG) chains, morphogen levels at the cell surface are 
reduced and the activity of signal transduction pathways is diminished. c) When glypicans are over-
expressed, morphogen levels at the cell surface are elevated owing to the increased binding capacity of the 
additional GAG chains. Signalling activity might be reduced owing to a shift of the equilibrium from 
signalling receptor activation to GAG binding. d) Glypicans can be shed from the cell surface by Notum-
mediated cleavage of the glycosyl-phosphatidylinositol (GPI) anchor. Shedding of glypicans might locally 
reduce morphogen activity at the cell surface and result in decreased activity of signal transduction 
 
 
Glypicans can be act in signal transduction also from inner of the cell after their 
internalization: the endocytic mechanism employed can be different, as association with 
lipid raft, caveolar uptakes, clathrin-mediated endocytosis or macropinocytosis and most 
probably could be depend as the nature and distribution of proteoglycans expressed on 
the cell surface. Glypicans are preferentially associated with lipid-raft, detergent-resistant 
microdomains enriched in relatively satured phospholipids, glycosphingolipids and 
cholesterol or in caveolae, which are specialized forms of lipid raft106,107. It is now 
becoming clear that lipid micro-environments on the cell surface also take part in the 
process of signal transduction because it is initiated by complex protein–protein 
interactions between ligands, receptors and kinases, for example. Lipid rafts containing a 
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given set of proteins that can change their size and composition in response to intra- or 
extracellular stimuli. This favours specific protein–protein interactions, resulting in the 
activation of signalling cascades108. How glypicans internalized can act in subsequent 
signaling pathways are still unknown.  
 
 
1.6  TUMOUR SPREAD AND METASTASIS FORMATION 
Metastasis, the spread of cancer from the primary tumor to circulation and other parts of 
the body remains a prominent problem in the search for a cure for cancer. The most 
deadly aspect of cancer is its ability to spread, or metastasize. Cancer cells initially group 
together to form a primary tumor. Once the tumor is formed, cells may begin to break off 
from this tumor and travel to other parts of the body. To metastasize, a cancer cell must 
break away from its tumor, invade either the circulatory or lymph system, which will 
carry it to a new location, and establish itself in the new site. Metastasis most commonly 
occurs by way of the bloodstream or the lymphatic system. Once in the bloodstream, the 
cancer cells now have access to every portion of the body. The lymphatic system has its 
own channels throughout the body like the circulatory system, through which a malignant 
cell can travel. These cancer cells that travel through the body are capable of establishing 
new tumors in locations remote from the site of the original disease109(Figure 11). 
Metastasis causes 90% of deaths from solid tumours and displays a remarkably diverse 
set of clinical manifestations. The risk of metastatic recurrence can sometimes be 
predicted from certain features of the primary tumour, as in the case of breast cancer, for 
which tumour size, histological grade, and gene-expression pattern are indicative of the 
risk of relapse. In other instances, metastatic disease presents itself with an unknown 
primary tumour source, rendering such correlations impossible to make. Moreover, 
disseminated tumour cells could theoretically also return to their original site (self-
seeding), thereby accounting for the progressive accumulation of aggressive cells in 
primary tumours and local recurrences. Work over the past three decades has identified 
many genes for which gain- or loss-of function confers autonomous proliferative activity, 
resistance to cell death cues, angiogenesis, altered cell adhesion and motility. In other 
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words, genetic alterations that mediate the initiation and local progression of tumours, 
and that collectively confer the prerequisites for metastasis, have been identified109. 
 
From: Steeg, P.S. Nature Reviews Cancer 3, 55-63 (January 2003) 
Figure 11: A schematic of the metastatic process, beginning with a) an in situ cancer surrounded by an 
intact basement membrane. b) Invasion requires reversible changes in cell–cell and cell–extracellular-
matrix adherence, destruction of proteins in the matrix and stroma, and motility. Metastasizing cells can c)| 
enter via the lymphatics or d) directly enter the circulation. e) Survival and arrest of tumour cells, and 
extravasation of the circulatory system follows. f) Metastatic colonization of the distant site progresses 
through single cells, which might remain dormant for years, to occult micrometastases and g) progressively 
growing, angiogenic metastases. 
 
However, we are only beginning to learn about the genetic determinants of metastasis 
proper; that is, those that mediate tumour cell invasion, intravasation, survival in 
circulation, scattering to distant tissues, extravasation into parenchyma, and colonization 
of vital organs95. Glypicans can have a crucial role in this context for their multiple roles 
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that can play in each steps of the metastatic process for their biological characteristic 
showed previously. 
Research is now focused on understanding in what ways cancer cells become potentially 
metastatic and aim to identify new cancer-associated gene-expression signatures as new 
tools to classify tumour subtypes, discern disease aetiology, predict risk of relapse, 
identify genes that mediate disease progression, and select optimal therapeutic options. 
 
 
1.7  MUSCULOSKELETAL SARCOMAS  
 
Bone and soft tissue malignant tumors are also called musculoskeletal sarcoma, which 
means a cancer of mesenchymal tissues, such as the bone, soft tissues, and connective 
tissue. Bone cancer is a relatively rare disease in which cancer cells grow in the bone 
tissue. Cancer may form in the bone or spread to the bone from another site in the body. 
When cancer starts in bone tissue, it is called primary bone cancer. When cancer cells 
travel to the bone from elsewhere, it is called secondary or metastatic cancer to the bone 
Primary tumors of bone can be divided into benign tumors and cancers. Common benign 
bone tumors may be neoplastic, developmental, traumatic, infectious, or inflammatory in 
etiology. Examples of benign bone tumors include osteoma, osteochondroma, aneurysmal 
bone cyst, and fibrous dysplasia. Malignant primary bone tumors include osteosarcoma, 
chondrosarcoma, Ewing's sarcoma, and other sarcoma types. Multiple myeloma is a 
hematologic cancer which also frequently presents as one or more bone tumors. The most 
common types of bone cancer include:  
• Osteosarcoma — a cancerous tumor of the bone, usually of the arms, legs, or 
pelvis; osteosarcoma is the most common primary cancer.  
• Chondrosarcoma — cancer of the cartilage; chondrosarcoma is the second most 
common primary cancer.  
• Ewing's sarcoma — tumors that usually develop in the cavity of the leg and arm 
bones  
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• Fibrosarcoma and malignant fibrous histiocytoma — cancers that develop in soft 
tissues (e.g., tendons, ligaments, fat, muscle) and move to the bones of the legs, 
arms and jaw  
• Giant cell tumor — a primary bone tumor that is malignant (cancerous) only 
about 10% of the time; most common in the arm or leg bones  
• Chordoma — primary bone tumor that usually occurs in the skull or spine 
 
 
Bone sarcoma % 
Osteosarcoma 47.75 
Ewing's sarcoma 17.57 
Chondrosarcoma 15 
Non-Hodgkin's lymphoma 9.01 
Plasma cell myeloma 6.31 
Other sarcomas 2.70 
Chordoma 0.90 
Langerhan's cell histiocytosis 0.90 
 
Modified from: Cancer Path. Reg. ‘03-‘04 And Time Trend Analysis. Department of Pathology, NCI 2007 
 
Table 5: Percentage of incidence of bone sarcomas in U.S.A.  
 
Osteosarcoma and Ewing’s sarcoma are two of the most common types of bone cancer 
and generally occur in children and young adults. Chondrosarcoma is cancer of the 
cartilage and is more common in adults. Chordoma is a type of bone cancer that typically 
starts in the lower spinal cord. Rare, soft-tissue sarcomas that begin in the bone include 
malignant fibrous histiocytoma (MFH) and fibrosarcoma. MFH makes up less than 1% of 
primary bone tumors. It is usually found in adults. The arms and legs, especially around 
the knee joint, are the most common sites for MFH to appear. Fibrosarcoma is also more 
common among adults, particularly during middle age, and most often begins in the 
thighbone. In 2008, an estimated 2,380 adults (1,270 men and 1,110 women) in the 
United States will be diagnosed with bone cancer. It is estimated that 1,470 deaths (820 
men and 650 women) from this disease will occur this year. Primary bone cancer 
accounts for less than 0.2% of all cancers. Osteosarcoma makes up 47% of all primary 
bone cancers, followed by Ewing’s family of tumors (17.5%), chondrosarcoma (15%), 
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chordoma and MFH/fibrosarcoma less than 5%110. Soft tissue sarcoma (STS) is cancer 
that develops in the tissues that support and connect the body111. Large majority of soft 
tissue tumours are benign, with a very high cure rate after surgery. Malignant 
mesenchymal neoplasms amount to less than 1% of the overall human malignant 
tumours, but are very hard-working to diagnose them and study their therapeutic protocol 
since there are more than 50 histological subtypes of STS. Benign mesenchymal tumours 
outnumber sarcomas by at least 100 to one112,113. Unlike the more common carcinomas, 
which are of epithelial origin, soft tissue sarcomas are of putative mesenchymal 
derivation and can involve connective tissue structures as well as viscera and integument 
anywhere in the human body, but about 40% occur in the arms or legs, 36% occur in the 
trunk or abdomen, and 11% occur in the head or neck112 whereas the percentage rest are 
located in the trunk wall, retroperitoneum, abdomen or other location114 (Figure 12). 
 
 
Figure 12: Soft Tissue Sarcoma anatomical site and % of distribution 
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Cancer begins when cells grow out of control, and instead of developing into normal 
cells, they form a tumor mass (lump). When sarcoma is small, it can go unnoticed or is 
ignored, since it does not usually cause problems at this stage. As sarcoma grows, it can 
interfere with the body's normal activities; it can also spread to other places in the body. 
STS can appear in any part of the body. The specific types of sarcoma are frequently 
named according to the normal tissue cells they most closely resemble (Table 6), rather 
than referring to an anatomical site (part of the body) as many other cancer types are 
named. 
Table 6: Types of Soft Tissue Sarcomas 
 
Name of STS Tissue type 
Angiosarcoma Blood or lymph vessels 
Ewing's sarcoma/PPNET (peripheral primitive neuroectodermal 
tumor) Mesenchymal stem cells 
Fibrosarcoma Fibrous tissue 
Gastrointestinal stromal tumor (GIST) Interstitial cells of the digestive tract 
Kaposi's sarcoma Blood vessels 
Leiomyosarcoma Smooth muscle 
Liposarcoma Fat tissue 
Myxofibrosarcoma (myxoid malignant fibrous histiocytoma [MFH]) Connective tissue 
Neurofibrosarcoma or malignant peripheral nerve sheath tumor Peripheral nerve 
Pleomorphic sarcoma, not otherwise specified (NOS) Unknown 
Rhabdomyosarcoma Skeletal muscle 
Synovial sarcoma Unknown 
 
Experts have identified many types and subtypes of sarcoma. Pathologists are now trying 
to find new ways to quickly determine a tumor's subtype, as this helps determine 
treatment. The definition of staging, hystotypes and the distribution of these varies over 
time and between researchers: the age-related incidence vary; embryonal 
rhabdomyosarcoma occurs almost exclusively in children, synovial sarcoma mostly in 
young adults, whereas pleomorphic high grade sarcoma, liposarcoma and 
leiomiosarcoma dominate in the elderly98,115. Most STS have no clearly defined etiology; 
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in rare case, genetics, irradiation, viral infections and immune deficiency have been 
found associated with the development of usually malignant soft tissue tumours; 
however, the large majority of soft tissue sarcomas seem to arise de novo, without an 
apparent triggering event112. Genetic mutations in pluripotent mesenchymal stem cells are 
believed to give rise to malignant clones, which lead to the formation of these disease 
types114. The determination of staging play a crucial role in the diagnosis: the American 
Joint Committee on Cancer (AJCC) have developed a Staging System in parallel with 
other cancer society; there are other factor that contributes in the diagnosis determination, 
among which the prognostic factors: site of primary tumor, the margin status of the 
resected tumor, size of STSs, if the tumor is de novo or recurrent lesion and finally but 
not back-burner the possible presence of molecular staging/prognosis markers. In a 
century of analysis of molecular biology of cancer, in that we can find a key to 
understand one of the elements of the tumour cascade in which we can use to fight back. 
Examination of a tumor's abnormal genetic code may help determine its characteristics 
and predict which treatments will be most effective. For at least one type of sarcoma, 
gastrointestinal stromal tumor (GIST), major advances have been made in targeted 
therapy (drug treatments targeted to specific genetic abnormalities in the sarcoma cell). 
Sarcoma is rare, accounting for about 1% of all cancers. In 2008, approximately 10,390 
people (5,720 males and 4,670 females) will be diagnosed with soft tissue sarcoma in the 
United States. An estimated 3,680 adults and children (1,880 males and 1,800 females) 
are expected to die of the disease this year. The overall five-year relative survival rate 
(percentage of patients who survive at least five years after the cancer is detected, 
excluding those who die from other diseases), combining all stages and types of sarcoma, 
is approximately 66% and the key determinant of survival is control of both local 
recurrence and as well as distant dissemination114. If the sarcoma is diagnosed at an early 
stage in an arm or leg, the five-year survival rate is 81% to 90%. If the sarcoma has 
spread or is located in another part of the body, then the five-year relative survival rate is 
much lower. Cancer survival statistics should be interpreted with caution. These 
estimates are based on data from thousands of cases of this type of cancer, but the actual 
risk for a particular individual may differ. It is not possible to tell a person how long he or 
she will live with sarcoma. Because the survival statistics are measured in five-year (or 
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sometimes one-year) intervals, they may not represent advances made in the treatment or 
diagnosis of this cancer97. 
 
1.7.1  MUSCULOSKELETAL SARCOMAS AND GLYPICANS 
 
Generally tumorigenesis is associated with changes in the PG synthesis. Heparan sulfate 
PGs are involved in several aspects of cancer biology including tumor progression, 
angiogenesis, and metastasis. Many functions of glypicans depend on their ability to bind 
and modulate the activity of components of the extracellular matrix (ECM). The ability of 
them to interact with other molecules, such as growth factors, is largely determined by 
the fine structure of the glycosaminoglycan chains. Glypicans can have both tumor 
promoting and tumor suppressing activities depending on the protein core, the GAG 
attached, molecules they associate with, localization, the tumor subtype, stages, and 
degree of tumor differentiation. Glypicans may promote local cancer cell growth in some 
cancer tissues, but inhibit tissue invasion and metastasis in others. HSPG degrading 
enzymes like heparanase, heparitinase, and other enzymes such as MMP are also 
important in tumor metastasis116. There are very few information that can cross-link Soft 
Tissue Sarcomas and glypicans: the scientific literature reports only careful study about 
glypican-3 and one case regarding glypican-5 of our interest. Several studies have shown 
that glypican 3 (GPC3) could be a useful diagnostic marker for hepatocellular carcinoma 
(HCC) and for differentiating HCC from nonneoplastic and preneoplastic liver disease. 
Furthermore, several other tumors revealed consistent expression of GPC3, including 
squamous cell carcinoma of the lung (27/50 [54%]), testicular nonseminomatous germ 
cell tumors (32/62 [52%]), and liposarcoma (15/29 [52%])117. GPC3 is also indentified as 
a novel important marker transcript that have not been previously associated and that can 
clearly discriminate between pediatric rhabdomyosarcomas (RMS) and Ewing's sarcomas 
(EWS), because the diagnostic classification of these cancers is frequently complicated 
by the highly similar appearance in routine histology, and additional molecular markers 
could significantly improve tumor classification118. Furthermore, in rhabdomyosarcomas 
it was show that there is a region of amplification at 13q31-32, a genomic region that 
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containing two genes: C13orf25 and GPC590,119,120; it was also demonstrate that 
constitutive overexpression and knockdown of GPC5 expression in this type of pediatric 
sarcoma cell lines increased and decreased cell proliferation, respectively90, and it was 
showed that glypican-5 increases proliferation through potentiating the action of the 
FGF2, HGF and Wnt1A121; GPC5 enhanced the signaling cascade of FGF2, that leads to 
mesodermal cell proliferation without induction of myogenic differentiation, and HGF 
and altered the cellular distribution of  the first; for this reason, it is possible that GPC5 
may influence growth factor signaling by retaining GFs either at the cell surface or by 
facilitating internalization90,121. This genomic amplification is an important element in 
cancer, because overexpression of gene through this model of action and other 
mechanisms can critically affect the behavior of tumour cells. This characteristic 
chromosomal imbalance, genomic amplification at 13q31-32, is frequently seen across 
broad range of tumor types122, including other sarcomas with poor prognosis like 
liposarcomas123.  
 
1.8  ORAL SQUAMOUS CELL CARCINOMA 
 
Oral cancer holds the eight positions in the cancer incidence ranking worldwide and oral 
squamous cell carcinoma (OSCC) representing in US 5% of all cancer for men and 2% 
for women124 and affects about 30,000 Americans each year. Over 95% of the OSSC are 
attributable to smoke, drink alcohol, or both. OSSC represent the most common cause of 
death for patients with oral cancer and have an important impact on physical appearance 
and on the ability to eat and speech. Loco-regional relapses determine a significant 
decrease of the quality of life in patients with important impairment on physical, 
functional and social domains due to the treatment of the primitive tumour111 (Figure 13). 
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Figure 13: Oral cavity 
 
 
 The chief risk factors for oral squamous cell carcinoma are smoking (especially > 2 
packs/day) and alcohol use. The combination of heavy smoking and alcohol abuse is 
estimated to raise the risk 100-fold in women and 38-fold in men. Squamous cell 
carcinoma of the tongue may also result from any chronic irritation, such as dental caries, 
overuse of mouthwash, chewing tobacco, or the use of betel quid. Oral human 
papillomavirus (HPV), typically acquired via oral-genital contact, may have a role in 
etiology125. About 26% of the cases are detected on the tongue. An additional 23% of 
cases arise from the oral portion of the pharynx. The oropharynx includes the tonsillar 
pillars, the soft palate, and the posterior wall of the pharynx. The lip accounts for an 
additional 20% of SCC cases. Most of these arise on the red portion of the lip (the 
vermilion). Another 17% of SCC cases arise in the mucosa on the floor of the mouth. The 
gingiva (9%), buccal mucosa (3%), and hard palate (2%) collectively give rise to 14%. It 
is important to know that the visible part of the tongue, the dorsum, is not a site where 
SCC develops; rather, it develops on the side (lateral surfaces) and underside (ventral 
surface), two areas not visible to cursory intraoral examination (Table 7). 
 
 37 
Table 7: Incidence of SCC by location 
 
General Location Incidence Specific Location 
Tongue 26% Lateral surface 
Ventral surface 
Oral Pharynx 23% Soft palate 
Tonsillar pillars 
Lip 20% Vermilion surface 
Floor of Mouth 17% Floor of mouth 
Gingiva 9% Gingiva 
Buccal Mucosa 3% Buccal mucosa 
Hard Palate 2% Hard palate 
 
 
It is the lateral tongue, the ventral tongue, the soft palate, the tonsillar pillars, and the 
floor of the mouth that account for two-thirds of the cases of intraoral SCC. These sites 
are designated as "high risk areas"126,127. Early, curable lesions are rarely symptomatic; 
thus, preventing fatal disease requires early detection by screening. Treatment is with 
surgery, radiation, or both. The overall 5-yr survival rate (all sites and stages combined) 
is >50%125. Unfortunately, currently implemented methods to predict disease 
reoccurrence such as staging and grading do not show a sufficiently accurate stratification 
of the patients, and molecular markers to predict disease progression are limited in 
number and efficiency; knowing in advance which patients have the higher risk of 
disease reoccurrence, despite a similar staging, would be important to focus resource only 
in a limited high-risk subgroup of patients. 
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1.8.1  PROTEOGLYCANS IN OSCC 
 
In the development of oral squamous cell carcinoma probably are involved several 
proteoglycans, but only for syndecan-1 there are data in the literature. In B lymphocytes 
and stratified squamous epithelia, syndecan-1 is proposed to function as a cell-cell 
adhesion molecule128,129,130. Furthermore, it plays an important role in the regulation of 
cell growth and differentiation during the developmental process20,21. During wound 
healing, syndecan-1 expression is enhanced in the proliferating epidermal cells, but it is 
also induced in the endothelial cells of the developing capillaries in granulation tissue131. 
In mature tissues, the expression of syndecan-1 is limited to the epithelial cells, with the 
exception of B cells and Leydig cells and it was previously shown that syndecan-1 
expression is reduced in epidermal keratinocytes during experimental skin carcinogenesis 
in mice131. In squamous cell carcinomas in people, a marked down-regulation of 
syndecan-1 expression is detected in SCCs of the head and neck as well as in the uterine 
cervix, when compared to the expression of syndecan-1 in corresponding normal 
epithelium. In fact, syndecan-1 has been proposed as a prognostic marker in SCCs of the 
head and neck132,133. There are no information about relationship between glypicans and 
OSCC, but is necessary a deeply analysis of proteoglycan pattern of expression on 
tumour cells to obtain a more clearly picture if there are other PGs involved apart from 
syndecan-1. 
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2.  MATERIALS AND METHODS 
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2.1  SURGICAL SPECIMENS 
 
Specimens were obtained surgically from 22 patients (8 women and 14 men; ages ranged 
from 32 to 88 years) with OSCC by the equip of Enrico Sesenna ( Maxillo-Facial Surgery 
Division, Head and Neck Department, University and Hospital of Parma, Parma, Italy)  
between 2007 and 2008 (Table 8). The normal oral epithelia (5 cases) as control were 
also evaluated. All specimens were aliquotated in 3 tissue cube of 1.5cm of thick and 
stored in RNAlater Solution (Ambion) for at last 1 day and then 2 aliquots were frozen at 
-80°C and one analyzed to extract  total RNA to processes for subsequent Real-time 
quantitative PCR studies. Tumoural biopsy were histologically diagnosed following 
TNM classification criteria, subdivided in four classes (T1T2, T3T4, age minor or major 
of 40 years correlate to TNM classification) and then compared with normal mucosal 
epithelium. 
Table 8: Surgical specimen analyzed 
 
COD 
BIOPSY 
TNM1 AGE 
1 T3T4N+ 41 
2 T3T4N- 32 
3 T3T4N+ 78 
4 T1T2N- 34 
5 T3T4N+ 61 
6 T1N- 38 
7 T1T2N- 43 
8 T3T4N+ 43 
9 T1T2N+ 50 
10 T2T3N+ 64 
11 
 
 
 
 
 
 
T3T4N+ 79 
12 T1T2N- 61 
13 T3T4 57 
14 T2N- 74 
15 T1T2N- 63 
16 T1T2N- 88 
17 T3T4N+ 72 
18 T3T4N+ 57 
19 T2N- nn2 
20 nd3 70 
21 nd nn 
22 nd nn 
1TNM classification provides a system for staging the occurrence of cancer., T refers to the primary tumour 
and is categorized as being 1-4 and a-d depending upon site, size and spread, N refers to the lymph nodes 
and they are categorized as being X, 0, 1, 2, or 3 depending upon if any, some or all are involved metastasis 
and +/- indicates if there are spread to lymph nodes or not without an accurate definition of how much of 
these are involved and M to the presence or absence of distant metastases. 2 nn: not note; 3 nd: not 
determined, in analysis. 
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2.2  CELLS  
 
All sarcoma cells (Table 9), both established cell lines and patient-derived, the last ones 
obtained from surgical specimens surgically removed from patients with sarcomas by 
equips of CRO Institute (Centre of Oncologic Reference, Aviano (PD), Italy), were 
cultured in DMEM (Dulbecco’s modified Eagle’s medium) with low Glucose (1.0 g/L), 
25 mM HEPES Buffer supplemented with Pen/Strep, L-Glutamine and 10% (v/v) FBS 
(fetal bovine serum). 
 
 
 
CELLS HYSTOTYPE 
NTI-AS-1 ANGIOSARCOMA 
NTI-CS-1 CHONDROSARCOMA 
Hs913T FIBROSARCOMA(metast. to lung) 
NTI-FS-1 FIBROSARCOMA 
NTI-FS-2 FIBROSARCOMA 
HT1080 FIBROSARCOMA (connective tissue) 
NTI-LMS-8 LEIOMYIOSARCOMA 
NTI-LMS-1 LEIOMYOSARCOMA 
NTI-LMS-2 LEIOMYOSARCOMA 
NTI-LMS-3 LEIOMYOSARCOMA 
NTI-LMS-5 LEIOMYOSARCOMA 
NTI-LMS-6 LEIOMYOSARCOMA 
NTI-LMS-7 LEIOMYOSARCOMA 
NTI-LMS-9 LEIOMYOSARCOMA 
NTI-LMS-10 LEIOMYOSARCOMA 
NTI-LMS-11 LEIOMYOSARCOMA 
NTI-LMS-12 LEIOMYOSARCOMA 
SK-UT-1 LEIOMYOSARCOMA (uterus) 
SK-LMS-1 LEIOMYOSARCOMA (vulva) 
SW872 LIPOSARCOMA 
NTI-LS-1 LIPOSARCOMA 
NTI-LS-2 
 
LIPOSARCOMA 
 
 
 
 
NTI-LS-3 LIPOSARCOMA 
NTI-LS-4 LIPOSARCOMA 
NTI-LS-5 LIPOSARCOMA 
NTI-LS-6 LIPOSARCOMA 
NTI-LS-7 LIPOSARCOMA 
NTI-MFH-1 
MALIGNANT 
FIBROHISTIOCYTOMA 
 
NTI-MFH-2 
MALIGNANT 
FIBROHISTIOCYTOMA 
NTI-MFH-3 
MALIGNANT 
FIBROHISTIOCYTOMA 
NTI-MFH-4 
MALIGNANT 
FIBROHISTIOCYTOMA 
NTI-MFH-5 
MALIGNANT 
FIBROHISTIOCYTOMA 
NTI-MFH-7 
MALIGNANT 
FIBROHISTIOCYTOMA 
NTI-MS-1 MULLERIAN SARCOMA 
NTI-OS-1 OSTEOSARCOMA 
SAOS2 OSTEOSARCOMA (bone) 
143B OSTEOSARCOMA (bone) 
Table 9: Sarcomas cells cultured; in blue established sarcoma cell lines; in red sarcomas cells patient-derived 
not yet characterized 
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CELL LINE HYSTOTYPE 
MG63 OSTEOSARCOMA (bone) 
GCT PLEOMORPH MALIGNANT 
HISTIOCYTOMA 
NTI-PNS-1 PNS SARCOMA 
NTI-RS-1 RHABDOMYOSARCOMA 
NTI-RS-2 RHABDOMYOSARCOMA 
RD RHABDOMYOSARCOMA 
(muscle) 
 
 
 
 
A204 RHABDOMYOSARCOMA 
(muscle) 
SJRH30 RHABDOMYOSARCOMA 
(muscle) 
NTI-STRO-2 STROMAL SARCOMA 
SW982 SYNOVIAL SARCOMA 
(synovium) 
MES-SA UTERINE SARCOMA (uterus) 
 
Table 9: continue 
 
 
2.3  DNA EXTRACTION 
 
Clones genomic DNA was prepared using InstaGeneTMMatrix 6% (Bio-Rad 
Laboratories) according to the manufacturer’s instructions. Qualitative PCR were 
optimized to test the DNA integrity and functionality amplifying the housekeeping gene 
RLP41, and amplifying Ampicillin resistance gene (β-lactamase) used for the selection in 
E. coli introduced into clones by transfections of pDisplay plasmids vectors using the 
respective primers shown in Table 10. 
 
 
2.4  RNA EXTRACTION AND RT-PCR 
 
Total RNA from each sarcoma cells was prepared by using Trizol® (Invitrogen) 
according to the manufacturer’s instructions and RNA quality was checked by 
Biophotometer (Eppendorf) and 1% agarose RNase free TAE agarose gel electrophoresis. 
Total RNA from each biopsy was prepared by using Trizol® according to the 
manufacturer’s instructions in combination with Qiagen RNAeasy Mini Kit (Qiagen) and 
RNA quality was checked by Thermo Scientific NanoDropTM Spectrophotometers, 1% 
agarose RNase free TAE agarose gel electrophoresis and Micro-electrophoresis run 
(Bioanalizer, Agilent, US). Total RNA (1µg) was reverse-transcribed with the 
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QuantiTect® Reverse Transcription Kit (Qiagen) according to the manufacturer’s 
instructions. Qualitative RT-PCR was performed at the beginning to check the presence 
of glypicans and syndecans (GPC1, GPC2, GPC3, GPC4, GPC5, GPC6, SDC1, SDC2, 
SDC3, and SDC4) mRNA and to test the integrity and functionality of these cDNA, and 
it was amplified, as internal control, RLP41 housekeeping gene using the primers listed 
follows (Table 10).  
 
Table 10: Table of primers used 
 
Gene Forward Reverse 
RLP41 GGAGGCCACAGGAGCAGAAA TGTCACAGGTCCAGGGCAGA 
GPC1 TGCTGCCTGATGACTACCTG GAGCACAGTAGACCAGCTTCA 
GPC2 ATCTGGTGAGGGGTTGGATGA GAGAGCCATCGGTAGATGAGG 
GPC3 CCTGATTCAGCCTTGGACAT TCCCTGGCAGTAAGAGCACT 
GPC4 TGGGAACGACGTGGACTTCTTTGA AGAAGGGACCCTGGTTTGCTTGTA 
GPC5 TATCCGGTCGTTGGAAGAAC GGTGGTCTTCATTCCATGCT 
GPC6 CAACATTGAGTCGGTCATGG ATTGTAGGGCCTGAAACGTG 
SDC1 GCTCTGGGGATGACTCTGAC GTATTCTCCCCCGAGGTTTC 
SDC2 CCAGCCGAAGAGGATACAAATG GCGTTCTCCAAGGTCATAGCTTCC 
SDC3 GAGCCTGACATCCCTGAGAG CCCACAGCTACCACCTCATT 
SDC4 GTCTGGCTCTGGAGATCTGG TGGGGGCTTTCTTGTAGATG 
Ampicillin GTGTCGCCCTTATTCCCTTT GGCACCTATCTCAGCGATCT 
 
To control no DNA contamination was performed a PCR with primers for RLP41 on 
reverse-transcribed without RNA as substrate. To quantify the exactly amount of each 
gene expressed in all the sample tested, it was performed a Real-time quantitative PCR 
using TaqMan low-density arrays (TLDA), as specified follow. 
 
Total RNA from each sarcoma cells and from each biopsy was prepared as described in 
the previous paragraph. Total RNA (1µg) was reverse-transcribed with the QuantiTect® 
Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. cDNA 
from RNA extracted from cell lines was quantified by spectrophotometer; cDNA from 
RNA obtained from surgical specimen was quantified by Biophotometer (Eppendorf). The 
integrity and functionality of these cDNA, was tested in qualitative RT-PCR amplifying 
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RLP41 housekeeping gene using the primers listed (Table 10). To control no DNA 
contamination was performed a PCR with primers for RLP41 on reverse-transcribed 
without RNA as substrate. Each TaqMan Low Density Array was designed for 
quantification of human genes and exploit TaqMan® technology, based on the fluorogenic 
5’ nuclease assay. The assays were chosen among the TaqMan Gene Expression Assay 
library (Table 11) and the cards were runned on ABI 7900 HT Fast Real-Time PCR 
System.  
 
Table 11: TaqMan Gene Expression Assay used 
 
Gene symbol Protein Assay ID 
GPC1 glypican-1 Hs00157805_m1 
GPC2 glypican -2 Hs00415099_m1 
GPC3 glypican-3 Hs00170471_m1 
GPC4 glypican-4 Hs00155059_m1 
GPC5 glypican-5 Hs00270114_m1 
GPC6 glypican-6 Hs00170677_m1 
SDC1 syndecan-1 Hs00896423_m1 
SDC2 syndecan-2 Hs00299807_m1 
SDC3 syndecan-3 Hs00206320_m1 
SDC4 syndecan-4 Hs00161617_m1 
CSPG4 NG2 Hs00426981_m1 
 
 
Gene expression was normalized to endogenous housekeeping gene 18S rRNA and it was 
chosen cDNA of human mesenchymal stem cells (hMSC) as sample calibrator, because 
all sarcomas analyzed came from mesenchymal cells, whereas cDNA of pool of RNAs 
extract from 5 normal oral epithelia surgical specimens was chosen as sample calibrator 
for the analysis of biopsy. An equal amount of input cDNA (100 ng) was used per 
reaction and loaded in one of the eight sample-loading port of the card. Results were 
analyzed using ABI PRISM 7900HT Sequence Detection System (ABI), and changes in 
gene expression levels were calculated using the “relative quantification method" based 
on the expression levels of a target gene versus a reference gene in each sample in 
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comparison to a sample calibrator (Figure 14) with the collaboration of Nelson Marmiroli 
staff, in particular with the supervision of Mariolina Gulli (Department of Environmental 
Science, University of Parma, Italy) . 
 
 
 
 
 
 
Figure 14: a) TaqMan Low Density Array; b) ABI 7900 HT Fast Real-Time PCR System.  
 
 
 
 
 
2.5  VECTORS AND CELL TRANSFECTION 
 
143B cells was transfected with the two types of expression vectors: pDisplay vector 
contained cDNA of glypican-5 Hemagglutinin A (HA)-tagged and pDisplay empty 
vector. The expression vector pDisplay containing ORF cDNA of GPC5 was gently 
provided by Guido David (University of Leuven-CME) and containing the box for G418 
resistance (Geneticin/Neomycin) (Figure 15). Both 143B stably transfected cells were 
cultured in DMEM (as before described) and G418 [800µg/ml].  
 
 
sample-loading 
48 reaction wells 
connected to 
each 
 sample-loading 
port 
spotted with  
TaqMan Gene  
a                                           b 
 46 
 
 
Figure 15: pDisplay vector 
 
The transfection was done using Metafectene™ Pro Reagent (Biontex, Germany) in 
condition predetermined to obtain maximum efficiency of transfection (Solution A: 0.8 
µg of vector DNA in 50µl medium free of serum and antibiotics, Solution B: 8 µl of 
Metafectene™ Pro transfection reagent in 50µl medium free of serum and antibiotics and 
both solutions applied on 60-70% cell confluence) and was performed an antibiotic 
monoclonal clones selection by G418 (to determinate the right concentration of antibiotic it 
was performed a dose-response curve at different concentration of G418 from 100ug/ml 
to 1mg/ml; he lower concentration which kill all cells in two weeks was [500µg/ml]; the 
clones were screened by PCR on DNA to amplify ampicillin gene and positive clones to 
ampicillin genes were screened further by RT-PCR for presence of GPC5 mRNA and 
ampicillin mRNA on positive clone in selection for respectively over-expression of 
GPC5 and empty vector (Figure 16). Positive clones were expanded and it was chosen 
the clone with the major level of glypican expression revealed by quantitative real time 
PCR. 
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Figure 16: Procedure for antibiotic monoclonal clones selection 
 
 
2.6  IMMUNOFLUORESCENCE  
 
Immunicytochemistry was done on the transfected cells to confirm the presence of the 
inserted constructs and to determine their cellular localization. 20.000 cells seeded on 
each coverslips were fixed after 24 hours using 4% paraformaldehyde (PFA); coverslips 
were washed in PBS1X (final concentration NaCl 137mM, KCl 2.7mM, Na2HPO4 
4.3mM, KH2PO41.47mM, adjust to a final pH of 7.4) and if necessary permeabilized 
using 0.1% Triton; coverslips were then incubated with primary antibody  anti-HA High 
Affinity (clone 3F10, Roche Diagnostic) used diluited 1:300 in a mixture that included 
10% NGS (normal goat serum) and PBS1X and with primary antibody anti-human 
Glypican-5 (clone 297716, R&D Systems) used diluited 1:200 in a mixture including 
10% NGS and PBS1X; after overnight incubation at 4°C, cells were incubated for an 
hour at room temperature with the secondary appropriate antibody in a mix with 10% 
NGS and PBS1X: secondary antibody against HA used was an anti-Rat Alexa 488 
DNA 
extraction 
and PCR 
Metafectene™ Pro solution B + pDisplay vector solution A 
48 hours post transfection 
  1st G418 selection 
  2nd G418 cloning selection 
cells 
are seeded at high dilution 
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(Invitrogen) diluited 1:400, and the secondary antibody used to reveal GPC5 was an anti-
Mouse tagged FITC or TRITC diluited 1:5000. Nuclei are revealed with incubation of 
coverslips with Hoechst 33258 staining and then the coverslips were mounted and 
observed under epifluorescence Nikon eclipse E600 microscope connected with a Nikon 
DXM1200 camera. 
 
 
2.7  FLOW CYTOMETRY  
 
500.000 over-expressing GPC5 cells and control cells were collected and incubated with 
250ng of direct-PE labeled monoclonal antibody anti-human/mouse GPC5 (clone 
297716, R&D System) on ice and then washed with PBS1X and resuspended in PBS1X 
for the analysis. As a control, cell in separate tube were treated with PE-labeled mouse 
IgG2A isotype control (clone HOPC-1, SouthernBiotech) antibody. All the sample were 
analyzed on fluorescence activated cell sorter (Coulter EPICS XL-MCL Flow Cytometer) 
with the collaboration of Marco Vitale groups (Department of Anatomy, Pharmacology 
and Forensic Medicine, University of Parma, Italy). 
 
 
2.8  WESTERN BLOTTING 
 
Cell extracts were prepared by lysing the cell for 10 min on ice in RIPA lysis buffer (final 
concentration Tris-HCl (pH 7.4) 50mM, NaCl 150mM, P-40 1%, Na-deoxycholate 0.5%, 
SDS 0.1%, EDTA 2mM, leupeptin 50µM, aprotinin 2µg/ml, soybean trypsin inhibitor 
2µg/ml, pepstatinNa3VO4 1µg/ml, NaF 1mM, Pefabloc SC 0.8mM) after collection from 
a 90mm dish and double washing with PBS1X. Protein concentration was measured by 
Bradford method134,135. Supernatant of stable cell lines were collected after 24 hours of 
culture incubation in DMEM serum free and concentrated utilizing methanol protocol136: 
400 µl of supernatants were mixed with 2.5 volumes of cool 100% methanol, incubated 
overnight at -20°C, washed the precipitate with cool 100% acetone, the pellet recovered 
were dissolved in sterile water and 20µl of concentrated media were denatured with 2X 
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sample buffer (final concentration Tris-HCl (pH 7.4) 0.065M, Glycerol 10.5%, 
SDS(10%) 21%, Bromophenol Blue(0.05%) 6.5% ). Protein extract diluited in 2X sample 
buffer and concentrated media were resolved on 8% SDS-PAGE and transferred to 
Hybond-P membranes (Amersham Pharmacia) over day. Western blot analysis were 
performed using the following primary antibodies: anti-HA High Affinity (3F10, Roche 
Diagnostics) used 1:2000 in TBS with 0.1% Tween® and 5% skim milk, anti-human 
Glypican-5 (R&D) used 1:500 in TBS with 0.1% Tween®, anti-actin (Sigma Aldrich) 
used 1:3000 in TBS with 0.1% Tween® and 1% skim milk as control. After incubation 
with the primary antibody, the blots were washed and incubated for 1 hour with the 
appropriate HRP (horseradish peroxidase)-conjugated secondary antibody; labeled 
proteins were detected with an ECL-Plus detection system (Amersham Pharmacia). 
 
 
 
2.9  PROLIFERATION ASSAY 
Viable cell numbers were estimated by the Trypan blue exclusion test. Cells were seeded 
in triplicate in 6-well culture plates at a density of 1x105 cells/well in DMEM with 10%  
and 1% of FBS in two different experiments. At various time points, 24, 48, 72 hours, 
cells in individual monolayer cultures were made into single-cell suspensions by 
trypsinization. The cell suspensions were then incubated for 3 min with Trypan blue dye 
and counted using a Burker chamber (Beckman Coulter-Z2). The cells remaining 
negative to the blue dye staining after Trypan blue exclusion were counted as viable cells. 
 
 
2.10  CELL ADHESION ASSAYS 
 
The adhesion assays were performed by using different purified ECM molecules: 
Collagen type III, Collagen type V, Laminin-1, Fibronectin and Vitronectin. The 
coverslips were coated using a 20 µg/ml of each matrix (Fibronectin, Laminin-1 and 
Vitronectin diluted in PBS1X and Collagens diluted in acetic acid 0.02N). The coatings 
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were done for 2 hours at 37°C for Fibronectin and at room temperature for the other 
molecules. Post-coating, 4x104 cell/ml cells were seeded on the coverslips coated in the 
same medium of the culture DMEM with 1% of FBS, as specified in proliferation assay. 
After 30 minutes from cells seeding, the cells were fixed in 4% PFA and if necessary 
permeabilized using 0.1% Triton; after the fixation the cells were subjected to 
immunocytochemistry and coverslips were incubated with primary antibody anti-HA (in 
the same condition previously reported) and primary antibody against actin, Phalloidin-
TRITC (Phalloidin has a specific binding for F-actin) used diluited 1:300 in PBS1X at 
room temperature; nuclei were stained as previously reported. Coverslips were mounted 
and observed under epifluorescence Nikon eclipse E600 microscope connected with a 
Nikon DXM1200 camera. 
 
 
 
2.11  CELL MIGRATION ASSAYS 
 
To examine haptotactic migratory behavior of GPC5 over-expressing cells on the same 
panel of isolated ECM molecules utilized in adhesion assay, it was performed a classical 
Transwell assay whereas to examine how GPC5 influenced the overall locomotory 
abilities of the cells it was used a conventional scratch assay. 
 
These assays were done using 8-µm pore FALCON HTS FluoroBlock Transwell system 
(Becton Dickinson) (Figure 17). The inserts of the Transwell were coated with the panel 
of different purified ECM molecules in the same condition showed in the adhesion 
assays. Cells were stained with Cell Tracker ORANGE (C2925 Invitrogen) and seeded 
into the insert at concentration of 1x105 cell/ml/transwell in DMEM with 1% of FBS; the 
lower chamber contained DMEM 10%. After 16 hours from cells seeding it was valued 
the number of migrated cells through the matrix component using the Inverted Nikon 
Eclipse TS 100 fluorescent microscope. 
 
 
 51 
 
 
 
 
 
Figure 17: FALCON HTS FluoroBlock Transwell system. 
 
 
Wound-healing-type (scratch) assays were performed by using Ibidi Culture System 
(80206 Ibidi, BioDiagnostic). The silicon insert creates 2 reservoirs separated by a 
400µm thick well. Cells were seeded into each well at concentration of 3x105 cell/ml in 
DMEM with 1% of FBS and were incubated at 37°C and 5% CO2. After 24 hours the 
cells reached confluence and the insert was removed by using sterile tweezers from the 
surface resulting in 2 defined cell patches separated by the original strip of 400µm 
(Figure 18). The used well were filled with DMEM with 1% of SFB. From this moment it 
was began the monitoring of the cell migration kinetic using Inverted Nikon Eclipse TS 
100 fluorescent microscope in phase contrast and were done microscope images at 
established time: 0 hours (start time), 3 hours, 5 hours, 7 hours and 24 hours (stop time) 
and were measured how much the front of migratory cells was moved from the start point 
during the time of observation with Adobe Photoshop program converting pixel of 
microscope images in µm. 
 
0.8mm 
8µm pore PET membrane 
lower compartment 
insert 
upper compartment 
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400 µm
a)                                                              b)
 
 
Figure 18: a) Steps of Wound healing assay using Ibidi Culture System; b) field of interest considered to 
take microscope images (magnification 10X). 
 
 
 
2.12  STATISTICAL ANALYSES 
 
In all experiments of adhesion and migration was applied as statistical test the Student's 
 t-test to determine the statistical significance of differences between means of three 
independent experiments, each in triplicate. Significance was defined as a P<0.05. 
 
 
 
 
 
 
 
a                                                                                b   
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3.  RESULTS 
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3.1  DEFINITION OF THE CONSTITUTIVE PROTEOGLYCAN SURFACE . 
.       PATTERN IN SARCOMA CELLS AND OSCC BIOPSIES 
  
A first part of the work was dedicated to the definition of the constitutive pattern of NG2, 
glypicans and syndecans expression in 31 of the sarcoma cells listed in (Table 9) at the 
transcriptional level. The results of this initial screening by qualitative PCR are reported 
in Table 12. 
 
 
Table 12: Expression pattern of PGs in sarcoma cells subdivided by hystotype. 
 
 
  NG2 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
GCT + +     + +  + + 
 
           
HT1080 + +   + +  + + + + 
Hs913T nd1 +      +  + + 
NTI-FS-1 + +    + + + + + + 
 
           
MES-SA 
 + +   +  +  +  
 
           
SK-LMS-1 + +     + +  + + 
SK-UT-1 + +    +  +  + + 
NTI-LMS-1 
         + + 
NTI-LMS-3 nd +    + + +  + + 
NTI-LMS-5 
 +   +  + + + + + 
NTI-LMS-6 +    + +   + + + 
NTI-LMS-8 nd +  nd +  nd + + + + 
 
 
  
 
  
 
    
SW872 nd +     + +  + + 
NTI-LS-1 + +      + + + + 
NTI-LS-2 
        +   
NTI-LS-3 
 +    nd + nd  + + 
NTI-LS-4 + +   +  + + + + + 
NTI-LS-5 + +      + + + + 
 
           
NTI-MS-1 
   + + + + + + + + 
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  NG2 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
NTI-MFH-1 nd +     + +  +  
NTI-MFH-3 nd +     +   + + 
NTI-MFH-4 +       + +  + 
 
           
143B  + + +  + + + + + + + 
MG63 +       + +  + 
SAOS2 +      +  + + + 
NTI-OS-1 +  + + + + + + + + + 
 
           
RD +   + +   + + + + 
A204 nd +     + +  + + 
SJRH30 + + + + + + + + + + + 
 
           
SW982 (+) +    + + +  + + 
 
 
          
NTI-PNS-1 nd +    + + +  + + 
 
 
1
 nd: not determined 
 
The panel of sarcoma cells analyzed represents several hystotypes of which six are 
correspondent by more than one cell. When looking at how PGs are distributed in this 
cells, it is evident that GPC2 and GPC3 are less frequently expressed (only in three 
distinct hystotypes), whereas SDC3 and SDC4 are the PG more widely expressed. GPC1, 
SDC1, SDC3 and SDC4 are expressed in all fibrosarcoma cells, whereas other PGs are 
differently expressed. In leiomyosarcoma cells, SDC3 and SDC4 are always present and 
GPC1 and SDC1 are expressed in all cells, with the exception of NTI-LMS-1 and NTI-
LMS-6; in three of seven leiomyosarcoma (NTI-LMS-5, -6 and -8) GPC4 and SDC2 are 
expressed and other PGs are differently present. All liposarcoma cells are similar in PG 
expression pattern except for NTI-LS-2, which expresses only SDC2. In the three 
malignant fibrohistiocytoma cells, seems to be at random PGs expression. In 
osteosarcoma cells there is a constant expression of NG2, SDC2 and SDC4 and two of 
them (143B and NTI-OS-1) express 10 PGs on the total of 11 with the expression of the 
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not frequent GPC2, whereas it is to note that NTI-OS-1 expresses also GPC3. All 
rhabdomyosarcoma cells always express SDC1, SDC2 and SDC4; RD and SJRH30 cells 
also express NG2, GPC3, GPC4 and SDC2. Finally, to note is that GPC3 is also 
expressed in the only Mullerian sarcoma cells analyzed.  
 
To the same aim to define the qualitative constitutive pattern of PG expression, we have 
analyzed 22 sample obtained from surgical specimens from patients with OSCC as 
previously reported (Table 8) subdivided in 4 classification groups that are been defined 
follow the sequent characteristics: patients in stage T1-T2 that show poor prognosis 
within or more than 40 years old and patients affected to advanced OSCC (T3-T4) with a 
good prognosis within or more than 40 years old (Table 13) and the results are reported 
in Table 14. Only two groups (sample TNM classified as T1T2 and age major of 40 years 
and sample TNM classified as T3T4 with age major of 40 years) are potentially 
informative, because the other two groups (sample TNM classified as T1T2 and age 
minor of 40 years and sample TNM classified as T3T4 with age minor of 40 years) are 
constituted at most of 2 samples; besides, 4 sample (19, 20, 21 and 22) were excluded 
from classification because are lacking of essential information (TNM classification 
and/or age). 
 
Table 13: Grouping of samples derived from surgical specimens and subdivided in relation to their TNM 
classification and age of patients. 
 
 
Classification groups N° sample 
I                  T1T2 < 40 yrs 2 
II                 T1T2 > 40 yrs 7 
III                T3T4 < 40 yrs 1 
IV                T3T4 > 40 yrs 8 
V                        excluded 4 
                                  total  22 
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Table 14: Expression pattern of PGs in surgical specimens subdivided in different classification groups 
 
 CSPG4 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
I            
4 
 +     + + +  + 
6 
      + + + +  
 
 II            
7 
 +    + + + + + + 
9 
      +  + +  
10 
      + + +  + 
12 
 +      + + + + 
14 +      + + + + + 
15 
 +  + +  + + +  + 
16 
 + +    + + + + + 
 
 III            
2 
      + +   + 
 
 IV            
1 
           
3 
 +     + + + + + 
5 + +   + + + + + + + 
8 +   +   + + + + + 
11 
 +  + +  + + + + + 
13 
 +  +   + + +  + 
17 
 +     + + + + + 
18 
      + + +  + 
             
V            
19  
   +  + + +  + 
20 
      + + +  + 
21  +   + + + +   + 
22  +      + + + + 
 
In a first analysis shown in Table 14 for the two groups in which there was a sufficient 
amount of cases, II and IV, we can observe that in II there is a constant expression of 
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SDC2 and 7 sample on a total of 8 express GPC6, SDC1, SDC3 and SDC4; GPC1 is 
expressed in the 50% of samples and there is a rare expression of NG2, GPC2, GPC3 
GPC4 and GPC5. In IV, with the exception of sample 1, that are lacking of the 
expression of all PGs, all of others samples express GPC6, SDC1, SDC2 and SDC4; five 
on a total of 7 sample express GPC1 and SDC3 and there is only one sample that express 
GPC5 and none express GPC2. It can be observed that in IV, GPC3 is expressed in three 
samples.  
 
To define more in detail the PG expression profile in both sarcoma cells and biopsies of 
OSCC it is essential to analyze the comparative PG expression in order to understand if 
different levels of expression of the same gene in various sarcoma hystotypes or 
classification groups in patients with OSCC is an informative element. 
 
Expression of NG2, glypicans and syndecans of sarcoma cells were normalized to 
endogenous housekeeping gene 18S rRNA and it was chosen cDNA of human 
mesenchymal stem cells (hMSC) as sample calibrator, because mesenchymal cell is the 
ancestral common cell of all sarcomas. The results of over-expression or down-regulation 
of PGs expression level are reported in Figure 19. In Figure 20 are reported the level of 
relative PG expression for sarcoma cells grouped in hystotypes only for which there are 
more than two sarcoma cells analyzed. 
 
 
 
 
 
 
Figure 19 (next page): TaqMan low-density arrays results: gene expression level down-regulate ⁬ddd  , up-
regulate ⁬ddd  or unchanged  ⁬ddd in comparison to hMSC as sample calibrator; ⁬ddd indicate that the 
cells not express the gene, ⁬ddd indicate that the gene is not expressed in both cells and sample calibrator, 
⁬ddd indicate that are not possible to calculate relative expression. 
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  CSPG4 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
GCT                       
 
HT1080                       
NTI-FS-1                       
 
MES-SA                       
 
SK-LMS-1                       
SK-UT-1                       
NTI-LMS-1                       
NTI-LMS-5                       
NTI-LMS-6                       
 
NTI-LS-1                       
NTI-LS-2                       
NTI-LS-3                       
NTI-LS-4                       
NTI-LS-5                       
 
NTI-MFH-4                       
 
NTI-MS-1                       
 
143B                        
MG63                       
SAOS2                       
NTI-OS-1                       
 
RD                       
SJRH30                       
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Figure 20: Level of relative expression of PGs of our interest in sarcoma cells subdivided in hystotypes.  
Data are normalized for the expression levels with hMSC, used as sample calibrator. 
N
G
2
G
PC
1
G
PC
2
G
PC
3
G
PC
4
G
PC
5
G
PC
5
SD
C
1
SD
C
2
SD
C
3
SD
C
4
 
> 
 61 
Results of qPCR show that in leiomyosarcoma cells all PG expressed are down-regulate 
and where there is the expression of NG2, mRNA level is 50% less than in the sample 
calibrator. In liposarcomas, PGs down-regulate have a very few level of expression, 
whereas NG2 expression is up-regulated twofold in two cells, in NTI-LS-4 GPC6 is up-
regulated more than 9 folds and in NTI-LS-1 SDC2 is expresses 96 folds in comparison 
to level of expression in hMSC. In osteosarcoma cells all PGs are down regulate with the 
exception of NG2 that is up-regulate in MG63 and SAOS2 of respectively 1 and more 
than 3 fold in comparison to sample calibrator. 
 
Expression of NG2, glypicans and syndecans in biopsies was normalized to endogenous 
housekeeping gene 18S rRNA and it was chosen cDNA of pool of RNAs extracted from 
5 normal oral epithelia surgical specimens as sample calibrator, because all oral 
squamous cell carcinomas developed from mucosal epithelial cells. The results of PG 
expression levels are reported in Figure 21 where it is indicate that for some PGs was not 
possible to calculate the expression. In Figure 22 are reported the level of relative PG 
expression for patients divided in classification groups (Table 13) only for which there 
are at last two biopsies analyzed. Results of SDC1, SDC2 and SDC4 expression levels 
show that these PGs are up-regulate in most of the biopsies analyzed and only in few 
sample are down-regulate. The classification group I shows results not interpretable 
because two samples are few for analyses.  In II all the samples have a similar pattern of 
expression, except for patients 10 that has SDC1 and SDC4 very few down-regulate in 
comparison to sample calibrator; SDC2 is the PG more express than others with a mean 
more than 20 folds in comparison to normal mucosal epithelium. Classification group IV 
show SDC1 expression level fluctuate nearly to the same level of the sample calibrator; 
the other two PGs, SDC2 and SDC4 are over-expressed in 85% of the samples and their 
expression levels in changeable within the group. In the biopsies of patients not 
classifiable, is interesting that one sample (20) is lacking of 80% of PGs expressions, 
other two (19 and 21) have a variable PG expression levels and the last biopsy (22) 
express 45% of PGs and all the PGs with expression level values are up-regulated more 
than 10 folds (SDC2 45 folds and SDC4 30 folds) in comparison to normal sample 
calibrator). 
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  NG2 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
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Figure 21: TaqMan low-density arrays results: gene expression level down-regulate ⁬ddd  , up-regulate 
⁬ddd  in comparison to pool of RNA obtained from normal mucosal epithelium as sample calibrator; 
⁬ddd indicate that the biopsy not express the gene, ⁬ddd indicate that the gene is not expressed in both 
biopsy and sample calibrator, ⁬ddd indicate that are not  
possible to calculate relative expression. 
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Figure 22: Level of relative expression of PGs in biopsies of OSCC subdivided into different classification 
groups I, II and IV. Data are normalized for the expression levels with normal oral epithelia used as sample 
calibrator. 
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Combining the result of PG expression obtained by RT-PCR and by TaqMan Low 
Density Array, we could define 24 different cellular PG models at the transcriptional 
level (Figure 23) with discrete surface PG pattern available for subsequent molecular 
manipulation, as gene transduction. Each cellular model can be in common between two 
or more sarcoma cell even if they belong to different hystotype. 
 
143BSJRH30 NTI-MS-1NTI-OS-1
HT1080
NTI-LS-4
NTI-LMS-5
NTI-FS-1
SW982
NTI-PNS-1
NTI-LMS-3
SK-LMS-1
GCT
RD NTI-LMS-6
NTI-LMS-8 MES-SASK-UT-1
NTI-LS-3
NTI-MFH-3
A204
SW872
NTI-LS-1
NTI-LS-5
MG63
NTI-MFH-4SAOS2NTI-MFH-1 NTI-LS-2NTI-LMS-1Hs913T
 
 
 
 
 
Figure 23: Cellular model available; two or more cells of different hystotype can be having the same 
pattern of PGs.  
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3.2  OVER-EXPRESSION OF GLYPICAN-5 IN 143B CELLS 
 
We have decided to analyze more in detail the function of glypican-5 because there is 
little information about its role in tumour progression and especially in sarcomas (as 
already discussed in the Introduction). By taking advantage of the PG patterns previously 
defined, we have chosen 143B cells to start to over-express GPC5 because this cells has a 
rather complex pattern of PGs expression that can allow us to combine different 
techniques, as in vitro transduction and/or RNAi mediated knockdown of individual cell 
surface PG in relation to their constitutive level of expression.  
 
We generated 5 stable clones of 143B cells over-expressing GPC5 (GPC5+ cells) with 
two of them over-expressing the gene at high level. We have chosen to use in in vitro 
assays one of the two clones with more than 90% of the cells over-expressing glypican-5 
as detected by Western blotting (Figure 24), immunocytochemistry and flow cytometry 
(Figure 25). The levels of expression of GPC5 mRNA in GPC5+ cells was assessed by 
qPCR and compared to control cells (CTR cells).  
 
CTR          GPC5+  KDa
250
60
45
*
 
 
 
Figure 24: Western blotting to detect the presence of glypican-5 on GPC5+ cells;* indicate a nonspecific 
band.  
 
β-actin 
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Figure 25: Detection of GPC5 in over-expressing cells by a) immunofluorescence (magnification 60X) and 
b) flow cytometry. 
 
 
Since in some pilot experiments we have noted that manipulation of given surface PGs 
frequently alters the relative expression of others, we evaluated how transduction of 
GPC5 affected the expression levels of the others PGs present on GPC5+ cells in 
comparison to CTR cells (Figure 26a). It is evident from the graph of levels of relative 
expression of the other PGs on the cell surface of stable GPC5+ cells that the over-
expression of GPC5 modulate almost all the expression of the other PGs and in detail the 
expression level of GPC1 and SDC4 is increased more than 5 folds and GPC2 is up-
regulated of 80 folds in comparison to the expression in the control cells and in Western 
blotting assay is confirmed this expression profile for glypican-2 with the result of the 
creation of two new and different cellular model (Figure 26b,c). 
 
a 
 
 
 
 
 
 
 
 
 
 
 
b 
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Figure 26: a) Levels of relative expression of PGs in GPC5 over-expressing cells (GPC5+ cells) in 
comparison to control cells (CTR cells); b) Western blotting of over-expression of glypican-2 in GPC5+ 
cells and c) CTR and GPC5+ new cellular model. 
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3.3  ANALYSIS OF POST-TRANSATIONAL MODIFICATIONS OF . . . . . . . . . 
. .    GLYPICAN-5  
 
In order to understand if glypican-5 could be shedded, as previously described for 
glypican-1 and glypican-3, from the cell surface by proteases/lipases-mediated cleavage 
of the glycosyl-phosphatidylinositol (GPI) anchor, a Western blotting analysis was 
performed in search of the N-terminal domain of the glypican-5 in the medium of 
cultured GPC5+ cells after 12 hours of starvation in serum free medium (Figure 27).  
 
CTR   GPC5+     M
KDa
250
100
60
45
CTR   GPC5+  
cell lysate medium cell lysate medium 
CTR   GPC5+   M CTR   GPC5+  
a)                                                              b)
 
 
 
Figure 27: Assessment of glypican-5 released by GPC5+ cells into the culture medium by cell surface 
shedding: a) Ponceau staining of a representative SDS gel; b) Western blotting to detect the presence of 
glypican-5 on GPC5+ cell lysate (as control) and on GPC5+culture medium; M is the protein ladder 
ColorBurst® (SIGMA). 
 
 
In this first experiment aimed at revealing the presence of glypican-5 in the culture 
medium of GPC5+ cells, it was not possible to detect the N-terminal portion of the PG; 
this suggested that there was little or no surface release of the transduced glypican-5 by 
enzyme-mediated shedding. 
a                                                           b 
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3.4  EFFECT OF GPC5 OVER-EXPRESSION ON CELL PROLIFERATION  
 
Two cellular models analyzed show similar proliferation and survival rates in optimal 
growth conditions (Figure 28) and in specific when cells are maintained in DMEM with 
1% of SFB and in the range of time within 24hours, and this results allows us to perform 
in vitro assay of adhesion and migration without the possibility that the different cellular 
vitality and proliferation can influence the results.  
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Figure 28: Growth curve of GPC5+ cells and CTR cells under optimal growth condition 
 
 
3.5  RESPONSE OF GPC5+ CELLS TO ECM  
 
We have examined the behavior of GPC5+ cells confronted with a first panel of isolated 
ECM molecules, including of Collagen type III and V, Laminin-1, Fibronectin and 
Vitronectin (Figure 29). Staining of cells for actin microfilaments reveals that over-
expression of GPC5 and the PG pattern associated with this over-expression could be 
implicated in the rearrangement of the cytoskeleton, especially when GPC5+ cells were 
seeded on Collagen type III, Fibronectin and Laminin-1, whereas glypican-5 not does 
seems to influence the formation of stress fibers when cells were allowed to adhere to 
other ECM molecules. 
 
Figure 29 (next page): Overview of GPC5+ adhesion on a selected panel of isolated ECM molecules 
(magnification.60X).
+ 
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GPC5+ cells adhered to and spread more tenaciously on Laminin-1 and Vitronectin 
(Figure 30); in fact GPC5+ cells spread 15% more than the CTR on Laminin-1 and almost 
twofold on Vitronectin. 
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Figure 30: Ability of GPC5+ to adhere and spread on 5 different component of ECM 
 
 
The relationship between over-expression of glypican-5 and the migration capacity of the 
cells on the same ECM molecules was assessed using a haptotactic migration assay, and 
it were found that, somewhat differently than what was seen in the spreading assay, cells 
over-expressing glypican-5 migrate more pronouncedly on Vitronectin and Collagen type 
III and less efficiently on Fibronectin in comparison to the behavior of control cells; and 
in the Figure 31 was showed that GPC5+ cells migrate less than 40% compared with CTR 
on Fibronectin and about more than 32% and 44% respectively on Vitronectin and type 
III Collagen. The haptotactic migration on the other matrices did not show significant 
difference between GPC5+ cells and CTR cells. 
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Figure 31: Haptotactic invasion assay on isolated molecules of ECM 
 
 
In order to examine also the overall locomotory abilities of GPC5+ cells we have used a 
conventional monolayer scratch injury assay and as it can be observed from the 
microscope images, GPC5+ cells and CTR cells show a similar migratory behavior within 
7 hours, then GPC5+ cells begins to shorten the distance, and at 24 hours cells over-
expressing glypican-5 have almost completed the coverage of the wound, while control 
cells have largely failed to do so (Figure 32). The analysis of results about the migration 
kinetic (Figure 33) points out this trend: at 7 hours GPC5+ cells have covered 25% of the 
scratch and only 7,5% more than the CTR cells without significant difference; at 24hours 
glypican-5 over-expressing cells have migrated for more than 80% of the wound and 
32% more than control cells. 
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Figure 32: Determining the role of glypican-5 in locomotory abilities of 143B over-expressing GPC5 cells; 
dashed yellow line marks the cells’ front at every time analyzed and at time 0 hours marks wound edge; 
dashed grey line indicate the middle of the scratch.  
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Figure 33: Migratory kinetics of GPC5+ 
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4.  DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
Accumulating evidence indicates that cellular function and phenotype are highly 
influenced by HSPGs, present at the cell-tissue-organ interface and they have been shown 
to have crucial regulatory roles in cellular control, coordinating and directing appropriate 
response to multiple ligands in normal physiological processes, such as embryogenesis137, 
as well as in pathophysiological condition, including the processes of tumor onset and 
progression138. With respect to cancer onset and progression, the structural complexity of 
tumour-cell HSPGs enables them to modulate directly or indirectly several aspects of 
tumour-cell phenotype, including growth kinetics, invasiveness and metastatic 
potential73. So a given tumour-derived HSPG can be pro-tumorigenic or anti-tumorigenic 
depending on whether it is anchored at the cell surface or present in the ECM as soluble 
factors139,91, as well as depending on the number and the sequences of heparan-sulphate 
chains attached to the core protein of HSPG and these opposing actions could be 
consequences of the ectopic signals produced by either their loss- or gain-of function82; 
besides; recent evidence highlights the fact that cancer cells, as part of the transformation 
process, alter their cell surface HSPGs profile, including differential expression of 
particular proteoglycans, as well as altering the HSPGs fine structure of a given 
proteoglycans91,100. In particular, glypicans, expressed predominantly during development 
and as HS-carrying molecules, are considered mainly regulators of heparin-binding 
growth factors in a tissue and cell specific manner42 and for the reason, given the ability 
of glypicans to regulate the activity of growth and survival factors, reports of the last 
years associate changes in glypican expression with tumor progression34,35. In this 
context, we have addressed our research to understanding how different cell surface 
proteoglycan patterns are involved in tumor and metastasis processes especially regarding 
the role that different pattern of surface HSPGs could have in sarcomas development and 
in the identification of new prognostic/predictive markers in defined class of patients with 
oral squamous cell carcinomas. Since there are not data in the literature, in order to define 
this hypothesis, we have started to systematically define for the first time, the constitutive 
pattern of cell surface PGs expression in a large panel of sarcoma cells belonging to 
different hystotype and in biopsy of selected patients affected by OSCC. The results show 
that all sarcoma cells express on average of 3 to 5 cell surface PGs simultaneously and 
there is a widespread down-regulation of GPC1, SDC2, SDC3 and SDC4, while the 
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others PGs are expressed mainly hystotype specific manner and almost totally down-
regulate, although from this data we are not able to define a specific profile that 
univocally is associated to a discrete hystotype. In fact we have outlined 24 different 
cellular models available and each of them could be in common with two or more 
sarcoma cell belonging to different hystotype. To the same aim, we have defined the cell 
surface PG patterns of 22 surgical specimens and the analysis of the result was carry out 
comparing only the two informative groups of classification (patients in stage T1T2 and 
T3T4 with more than 40 years old) of the 4 different determined on the basis of main 
characteristics that are of great importance to the classification of the tumor in oncologic 
patient. The data show that in the first informative groups there is a widespread but not 
overall over-expression of GPC6, SDC1, SDC2, SDC3 and SDC4 with rare expression of 
the others PGs in comparison to the second groups considered, which express in all the 
sample GPC6, SDC1 (over-expressed in more than 50% of samples), SDC2 and SDC4, 
both next to always over-expressed and GPC3 in the 37% of the specimens analyzed; 
both group express GPC1 in ca. 60% of samples. Remain to understand the significance 
of these results: the sarcoma and OSCC cell phenotype could be partly determined by 
surface PG expression pattern? And there are some PGs that could lead to the 
identification of new therapeutic target? The expression of GPC1 could regulate invasion 
and the response to TGFβ family of growth factors signaling74,75,77,78; SDC2, SDC3 and 
SDC4 could modulate especially the FGF2, TGFβ and Hh signalling26,29 and be 
implicated in matrix assembly24,25 and regulation of fibronectin signaling and matrix 
contraction together with tenascin-C30. Interesting is the fact that the patients of group of 
classification II express SDC1 and SDC2 at more high level in comparison to IV and this 
one express GPC3 that is not express in the normal oral epithelial and that seems similar 
to what happen in hepatocellular carcinoma64,65,66,67,69,70,71,72; it is necessary to increase 
the number of patients so that we will can have more PGs information to make 
comparison between groups of interest. In order to examine more in depth how a define 
PG could influences the phenotype of a sarcoma cell, we have create a new cellular 
model of 143B cells over-expressing glypican-5, because about the involvement of this 
cell surface PG in tumor, especially in sarcomas, there are very few information90 and the 
osteosarcoma cell lines was a suitable model for their rather complex pattern of PG 
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expression. Our model has a determined cell surface PG patterns, similar to 143B 
parental cell lines but with over-expression of glypican-2 at high level and syndecan-4 as 
a results of the over-expression of GPC5, because the manipulation of a given surface 
PGs alters the relative expression of others as previously noted26. The significance of 
HSPGs in cell regulation is further emphasized by the presence of HS-binding domains in 
cell adhesion proteins of the ECM, such as Fibronectin. The concerted action of cell 
surface integrins and HSPGs directs cell attachment to these ECM substrates, leading to 
the formation of focal adhesions12. The capacity of HSPGs to interact with both the 
matrix architecture and soluble ligands defines a unique combination of properties that 
enables normal cells to sense, respond to and controlling influences in their environment. 
Cancer cells employ various mechanisms to exploit these properties and gain a survival 
advantage100. Sets out from the assumption that HSPGs on the surface of tumor cell 
seems to mediate their effects by regulating growth factor signaling, cell adhesion, 
proliferation, migration and angiogenesis1,91,92 and because the unique structural 
complexity of tumour-cell HSPGs enable them to modulate directly and/or indirectly 
several aspects of tumour-cell phenotype, including growth kinetics, invasiveness and 
metastatic potential75,76, we have decided to analyze 143B over-expressing glypican-5 
cellular model for its ability to adhere and migrate in comparison to a control cells and in 
response to different matrix molecules in vitro, because data in literature suggest that a 
specific pattern of a cell surface HSPGs can be pro-tumorigenic or anti-tumorigenic 
depending on whether molecules of ECM can binds the GAGs chain of HSPGs or 
depending on whether soluble factors in the ECM can bind the cell surface receptors, 
which link membrane HSPGs as co-receptor. In 143B over-expressing glypican-5 cells, 
GPC5 and the PG pattern associated could be implicated in the rearrangement of 
cytoskeleton, especially in response to Collagen type III, where the cells show a 
formation of protrusion lamellipodia-like, Fibronectin and Laminin-1, whereas seems not 
to interfere with the formation of stress fibers when adhere on the other ECM molecules 
analyzed; besides, GPC5 seems to have a preference of adhesion to Laminin-1 and 
Vitronectin. In contrast, when it was observed the invasive ability of GPC5+ cells on the 
same molecules of ECM, cells over-expressing glypican-5 migrate more pronouncedly on 
Vitronectin and Collagen type III and less on Fibronectin. These results suggest that, 
 78 
when abundantly expressed on the cell surface, GPC5 differentially regulate cell adhesion 
and migration to selected ECM components and future perspective are to investigate the 
significance of this phenomenon. GPC5 seems to influence also the overall locomotory 
abilities of the cells. Other ways which syndecans and glypicans can relay our contribute 
to signal transduction are their shedding in the extracellular environment or their 
internalization within the endocytotic vesicle, in which the GPI-anchored protein can be 
endocytosed and degraded, cleaved and released, vesiculated, or exchanged onto another 
cell102. In the preliminary analysis of post translational modification of glypican-5, seems 
that GPC5 is not released in the extracellular environment, and probably it is favourite an 
internalization process; remain to define more in particular this outcome, because this 
results could be due to a partial or total lack of enzyme for the cleavage on the GPI 
anchor or there are post-translational modification that alter the amino acidic structure of 
the protein and prevent proteases/lipases from doing cleavage or more simply the 
experimental procedure don’t allows us to detect the N-terminal of the glypican-5 in the 
medium. 
Gaining better inside into the mechanism that result in the behavior observed of these 
models, could be a new perspective in the understanding how these molecules regulate 
different aspects of cancer biology. “Glycoprofiling” cancer cells by mapping cell surface 
HSPGs might provide an opportunity to develop important prognostic tool for cancer 
detection and staging. The cell surface PG pattern could supply to all the scientific 
community important data to the prediction of cancer growth or metastatic potential, as 
well as its potential response to therapy. It is reasonable to think that a more deep 
knowledge of glypicans involvement in normal and pathological processes, as well as the 
identification of correlate signaling, should provide a wider clinical approach for the 
development of targeted therapeutics.  
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